1 Summary of Major Modifications and Explanatory Notes 2025 Prohibited List SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) PROHIBITED SUBSTANCES S0. Non-Approved Substances • S-107 and S48168 (ARM210) were added to S0 as examples of the class of ryanodine receptor-1-calstabin complex stabilizers. The ryanodine receptor-1-calstabin complex is a major component of calcium storage and release, serving to maintain skeletal muscle function. S3. Beta-2 Agonists • Based on a recent publication1 on potential performance-enhancing doses of inhaled formoterol, the dosing intervals were updated to ensure that ergogenic effects are not achieved. These new 12-hourly dosing intervals are consistent with manufacturers’ recommended use; the maximum delivered dose is unchanged at 54 micrograms over 24 hours. 1 Jeppesen JS, Jessen S,Thomassen M, Backer V, Bangsbo J, Hostrup M. Inhaled beta2-agonist, formoterol, enhances intense exercise performance, and sprint ability in elite cyclists. Scand J Med Sci Sports. 2024;34:e14500.doi:10.1111/sms.14500 2 S5. Diuretics and Masking Agents • Xipamide was added as an example of a diuretic. S4. Hormone and Metabolic Modulators • Elacestrant was added as an example of an anti-estrogen. • Mitochondrial open reading frame of the 12S rRNA-c (MOTS-c) was added as an example of an AMP-activated protein kinase activator. • For clarity, S519 and S597 were added as examples of insulin-mimetics. Insulin- mimetics compounds or selective insulin receptor modulators (SIRMs) mimic insulin action by binding to the insulin receptor2. 2 a) Schäffer L, Brissette RE, Spetzler JC, Pillutla RC, Østergaard S, Lennick M, Brandt J, Fletcher PW, Danielsen GM, Hsiao KC, An- dersen AS, Dedova O, Ribel U, Hoeg-Jensen T, Hansen PH, Blume AJ, Markussen J, Goldstein NI. Assembly of high-affinity insulin receptor agonists and antagonists from peptide building blocks. Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4435-9. doi:10.1073/ pnas.0830026100 b) Schäffer L (2006) Pharmaceutically active insulin receptor-modulating molecules. PCT Int Appl WO2006018450 3 PROHIBITED METHODS M1. Manipulation of Blood and Blood Components • Donation of blood or blood components (e.g. plasma, red blood cells, white blood cells, platelets and peripheral blood stem cells) including by apheresis is not prohibited when performed in a collection center accredited by the relevant regulatory authority of the country in which it operates. M3. Gene and Cell Doping • Minor editorial change was made for clarity. 4 SUBSTANCES AND METHODS PROHIBITED IN-COMPETITION PROHIBITED SUBSTANCES S6. Stimulants • Hydrafinil (fluorenol) was changed from S6.B to S6.A, as this substance is more potent than modafinil and is not licensed for medical use. • Midodrine and tesofensine were added as examples of specified stimulants. • Guanfacine was clarified as not prohibited. PROHIBITED IN PARTICULAR SPORTS P1. Beta-Blockers • Based on information provided by International Ski and Snowboard Federation (FIS), the skiing/snowboarding disciplines of ski jumping, freestyle aerials/halfpipe and snowboard halfpipe/big air were removed. MONITORING PROGRAM • Fentanyl and tramadol were added to monitor patterns of Out-of-Competition use. * For further information on previous modifications and clarifications, please consult the Prohibited List Frequently Asked Questions at https://www.wada-ama.org/en/ prohibited-list#faq-anchor. https://www.wada-ama.org/en/prohibited-list#faq-anchor https://www.wada-ama.org/en/prohibited-list#faq-anchor

1 Summary of Major Modifications and Explanatory Notes 2024 Prohibited List SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) PROHIBITED SUBSTANCES Subclasses of sections S1, S2, S4, M1, M2, M3 and S6 of the Prohibited List were renumbered for better clarity throughout the document to avoid any misinterpretation of subclasses but there was no change in classification. S0. Non-Approved Substances • 2,4-Dinitrophenol (DNP) and troponin activators (e.g. Reldesemtiv and Tirasemtiv) were listed as examples. S1. Anabolic Agents • Trestolone (7ɑ-methyl-19-nortestosterone, MENT), dimethandrolone (7ɑ,11ß-Dimethyl- 19-nortestosterone) and 11ß-methyl-19 nortestosterone were added as examples of nandrolone (19-nortestosterone) analogues. S2. Peptide Hormones, Growth Factors, Related Substances, and Mimetics • S2.2.1 was reworded under the heading of “Testosterone-stimulating peptides in males” for clarity. This specifies that buserelin, deslorelin, goserelin, histrelin, leuprorelin, nafarelin and triptorelin are examples of Gonadotrophin-Releasing Hormone (GnRH) agonist analogues, with histrelin added as a new example. Kisspeptin and its agonist analogues, which act to stimulate GnRH secretion, and consequently testosterone, were also added. • S2.2.2 : Tetracosactide (ACTH 1-24) was added as an example, as it is the first 24 amino acid portion of natural corticotrophin (ACTH), and possesses the full biological activity of the natural hormone. • S2.2.4: Capromorelin and ibutamoren (MK-677) were added as examples of growth hormone secretagogues (GHS), which are mimetics of the natural hormone, ghrelin, that stimulates the production of growth hormone (GH) and, in turn, insulin-like growth factor 1 (IGF-1). • S2.3: The INN name for recombinant human IGF-1, mecasermin, was added. 2 S5. Diuretics and Masking Agents • Editorial changes were made to section S5 to improve clarity. Conivaptan and mozavaptan were added as further examples of vaptan drugs. S4. Hormone and Metabolic Modulators • S4.4.1 was updated to include Rev-Erb-ɑ agonists and as example, SR9011 was added and SR9009 was relocated. 3 PROHIBITED METHODS M1. Manipulation of Blood and Blood Components • Donation by Athletes of plasma or plasma components by plasmapheresis is no longer prohibited when performed in a registered collection center. 4 S7. Narcotics SUBSTANCES AND METHODS PROHIBITED IN-COMPETITION PROHIBITED SUBSTANCES 1 a) Holgado D, Zandonai T, Zabala M, Hopker J, Perakakis P, Luque-Casado A, Ciria L, Guerra-Hernandez E, Sanabria D. Tramadol effects on physical performance and sustained attention during a 20-min indoor cycling time-trial: A randomised controlled trial. J Sci Med Sport. 2018 Jul;21(7):654-660. b) Mauger L, Thomas T, Smith S, Fennell C. Tramadol is a performance-enhancing drug in highly trained cyclists: a randomized con- trolled trial. J Appl Physiol. 2023 Jul;135: 467–474. • Tramadol is prohibited In-Competition as of 1 January 2024 as approved by the Executive Committee on 23 September 2022. Tramadol has been on the WADA Monitoring Program for some years. Monitoring data has indicated significant Use in sports including cycling, rugby and football. Tramadol abuse, with its dose-dependent risks of physical dependence, opiate use disorder and overdoses in the general population, is of concern and has led to it being a controlled drug in many countries. Research studies funded by WADA1 have confirmed the potential for tramadol to enhance physical performance in sports. The recommended washout period§ will be communicated before 1 January 2024. § The “washout period” refers to the time from the last administered dose to the time of the start of the In-Competition period (i.e. beginning at 11:59 p.m. on the day before a Competition in which the Athlete is scheduled to participate, unless a different period was approved by WADA for a given sport). S6. Stimulants • 2-phenylpropan-1-amine (BMPEA, ß-methylphenethylamine) was added as an example of a specified stimulant due to its presence in dietary supplements. • Tramazoline was added as an imidazoline derivatives under Exceptions. 5 *The “washout period” refers to the time from the last administered dose to the time of the start of the In-Competition period (i.e. beginning at 11:59 p.m. on the day before a Competition in which the Athlete is scheduled to participate, unless a different period was approved by WADA for a given sport). This is to allow elimination of the glucocorticoid to below the reporting level. ** Oral routes also include e.g. oromucosal, buccal, gingival and sublingual. • The Washout Period Table is also found in the List FAQ https://www.wada-ama.org/en/ prohibited-list#faq-anchor Route Glucocorticoid Washout period* Oral** All glucocorticoids; 3 days Except: triamcinolone; triamcinolone acetonide 10 days Intramuscular Betamethasone; dexameth- asone; methylprednisolone 5 days Prednisolone; prednisone 10 days Triamcinolone acetonide 60 days Local injections (including periarticular, intra-articular, peritendinous and intraten- dinous) All glucocorticoids; 3 days Except: prednisolone; prednisone; triamcinolone acetonide; triamcinolone hexacetonide 10 days Rectal All glucocorticoids; 3 days Except: triamcinolone dia- cetate; triamcinolone ace- tonide 10 days • The minimum washout periods following rectal administration of glucocorticoids are now included in the Glucocorticoid Washout Table; glucocorticoids remain prohibited In-Competition when administered by the rectal route. These washout periods are based on the use of these medications according to the maximum manufacturer’s licensed doses: S9. Glucocorticoids https://www.wada-ama.org/en/prohibited-list#faq-anchor https://www.wada-ama.org/en/prohibited-list#faq-anchor 6 • Salmeterol and vilanterol were removed as the required prevalence data were obtained. • Tramadol was removed as it is now prohibited under S7: Narcotics . • Tapentadol and dihydrocodeine were added to monitor patterns of use In Competition. • The GLP-1 analogue semaglutide was added to examine the prevalence and pattern of use in sport. * For further information on previous modifications and clarifications, please consult the Prohibited List Frequently Asked Questions at https://www.wada-ama.org/en/ prohibited-list#faq-anchor. MONITORING PROGRAM https://www.wada-ama.org/en/prohibited-list#faq-anchor https://www.wada-ama.org/en/prohibited-list#faq-anchor

1 Summary of Major Modifications and Explanatory Notes 2024 Prohibited List SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) PROHIBITED SUBSTANCES Subclasses of sections S1, S2, S4, M1, M2, M3 and S6 of the Prohibited List were renumbered for better clarity throughout the document to avoid any misinterpretation of subclasses but there was no change in classification. S0. Non-Approved Substances • 2,4-Dinitrophenol (DNP) and troponin activators (e.g. Reldesemtiv and Tirasemtiv) were listed as examples. S1. Anabolic Agents • Trestolone (7ɑ-methyl-19-nortestosterone, MENT), dimethandrolone (7ɑ,11ß-Dimethyl- 19-nortestosterone) and 11ß-methyl-19 nortestosterone were added as examples of nandrolone (19-nortestosterone) analogues. S2. Peptide Hormones, Growth Factors, Related Substances, and Mimetics • S2.2.1 was reworded under the heading of “Testosterone-stimulating peptides in males” for clarity. This specifies that buserelin, deslorelin, goserelin, histrelin, leuprorelin, nafarelin and triptorelin are examples of Gonadotrophin-Releasing Hormone (GnRH) agonist analogues, with histrelin added as a new example. Kisspeptin and its agonist analogues, which act to stimulate GnRH secretion, and consequently testosterone, were also added. • S2.2.2 : Tetracosactide (ACTH 1-24) was added as an example, as it is the first 24 amino acid portion of natural corticotrophin (ACTH), and possesses the full biological activity of the natural hormone. • S2.2.4: Capromorelin and ibutamoren (MK-677) were added as examples of growth hormone secretagogues (GHS), which are mimetics of the natural hormone, ghrelin, that stimulates the production of growth hormone (GH) and, in turn, insulin-like growth factor 1 (IGF-1). • S2.3: The INN name for recombinant human IGF-1, mecasermin, was added. 2 S5. Diuretics and Masking Agents • Editorial changes were made to section S5 to improve clarity. Conivaptan and mozavaptan were added as further examples of vaptan drugs. S4. Hormone and Metabolic Modulators • S4.4.1 was updated to include Rev-Erb-ɑ agonists and as example, SR9011 was added and SR9009 was relocated. 3 PROHIBITED METHODS M1. Manipulation of Blood and Blood Components • Donation by Athletes of plasma or plasma components by plasmapheresis is no longer prohibited when performed in a registered collection center. 4 S7. Narcotics SUBSTANCES AND METHODS PROHIBITED IN-COMPETITION PROHIBITED SUBSTANCES 1 a) Holgado D, Zandonai T, Zabala M, Hopker J, Perakakis P, Luque-Casado A, Ciria L, Guerra-Hernandez E, Sanabria D. Tramadol effects on physical performance and sustained attention during a 20-min indoor cycling time-trial: A randomised controlled trial. J Sci Med Sport. 2018 Jul;21(7):654-660. b) Mauger L, Thomas T, Smith S, Fennell C. Tramadol is a performance-enhancing drug in highly trained cyclists: a randomized con- trolled trial. J Appl Physiol. 2023 Jul;135: 467–474. • Tramadol is prohibited In-Competition as of 1 January 2024 as approved by the Executive Committee on 23 September 2022. Tramadol has been on the WADA Monitoring Program for some years. Monitoring data has indicated significant Use in sports including cycling, rugby and football. Tramadol abuse, with its dose-dependent risks of physical dependence, opiate use disorder and overdoses in the general population, is of concern and has led to it being a controlled drug in many countries. Research studies funded by WADA1 have confirmed the potential for tramadol to enhance physical performance in sports. The recommended washout period§ will be communicated before 1 January 2024. § The “washout period” refers to the time from the last administered dose to the time of the start of the In-Competition period (i.e. beginning at 11:59 p.m. on the day before a Competition in which the Athlete is scheduled to participate, unless a different period was approved by WADA for a given sport). S6. Stimulants • 2-phenylpropan-1-amine (BMPEA, ß-methylphenethylamine) was added as an example of a specified stimulant due to its presence in dietary supplements. • Tramazoline was added as an imidazoline derivatives under Exceptions. 5 *The “washout period” refers to the time from the last administered dose to the time of the start of the In-Competition period (i.e. beginning at 11:59 p.m. on the day before a Competition in which the Athlete is scheduled to participate, unless a different period was approved by WADA for a given sport). This is to allow elimination of the glucocorticoid to below the reporting level. ** Oral routes also include e.g. oromucosal, buccal, gingival and sublingual. • The Washout Period Table is also found in the List FAQ https://www.wada-ama.org/en/ prohibited-list#faq-anchor Route Glucocorticoid Washout period* Oral** All glucocorticoids; 3 days Except: triamcinolone; triamcinolone acetonide 10 days Intramuscular Betamethasone; dexameth- asone; methylprednisolone 5 days Prednisolone; prednisone 10 days Triamcinolone acetonide 60 days Local injections (including periarticular, intra-articular, peritendinous and intraten- dinous) All glucocorticoids; 3 days Except: prednisolone; prednisone; triamcinolone acetonide; triamcinolone hexacetonide 10 days Rectal All glucocorticoids; 3 days Except: triamcinolone dia- cetate; triamcinolone ace- tonide 10 days • The minimum washout periods following rectal administration of glucocorticoids are now included in the Glucocorticoid Washout Table; glucocorticoids remain prohibited In-Competition when administered by the rectal route. These washout periods are based on the use of these medications according to the maximum manufacturer’s licensed doses: S9. Glucocorticoids https://www.wada-ama.org/en/prohibited-list#faq-anchor https://www.wada-ama.org/en/prohibited-list#faq-anchor 6 • Salmeterol and vilanterol were removed as the required prevalence data were obtained. • Tramadol was removed as it is now prohibited under S7: Narcotics . • Tapentadol and dihydrocodeine were added to monitor patterns of use In Competition. • The GLP-1 analogue semaglutide was added to examine the prevalence and pattern of use in sport. * For further information on previous modifications and clarifications, please consult the Prohibited List Frequently Asked Questions at https://www.wada-ama.org/en/ prohibited-list#faq-anchor. MONITORING PROGRAM https://www.wada-ama.org/en/prohibited-list#faq-anchor https://www.wada-ama.org/en/prohibited-list#faq-anchor

WORLD ANTI-DOPING CODE INTERNATIONAL STANDARD PROHIBITED LIST 2025 This List shall come into effect on 1 January 2025. https://www.wada-ama.org/en 2 SUBSTANCES & METHODS PROHIBITED AT ALL TIMES S0 Non-approved substances.........................................................................................................4 S1 Anabolic agents................................................................................................................................5 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. male hypogonadism. S2 Peptide hormones, growth factors, related substances, and mimetics............7 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. anaemia, male hypogonadism, growth hormone deficiency. S3 Beta-2 agonists.................................................................................................................................9 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. asthma and other respiratory disorders. S4 Hormone and metabolic modulators...................................................................................10 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. breast cancer, diabetes, infertility (female), polycystic ovarian syndrome. S5 Diuretics and masking agents................................................................................................ 12 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. heart failure, hypertension. M1 – M2 – M3 Prohibited Methods............................................................................................. 13 SUBSTANCES & METHODS PROHIBITED IN-COMPETITION S6 Stimulants........................................................................................................................................... 14 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. anaphylaxis, attention deficit hyperactivity disorders (ADHD), cold and influenza symptoms. S7 Narcotics............................................................................................................................................. 16 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. pain, including from musculoskeletal injuries. S8 Cannabinoids.................................................................................................................................... 17 S9 Glucocorticoids............................................................................................................................... 18 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. allergy, anaphylaxis, asthma, inflammatory bowel disease. SUBSTANCES PROHIBITED IN PARTICULAR SPORTS P1 Beta-blockers................................................................................................................................... 19 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. heart failure, hypertension. INDEX...................................................................................................................................................................20 TABLE OF CONTENTS Please note that the list of examples of medical conditions below is not inclusive. 3 Introduction The Prohibited List is a mandatory International Standard as part of the World Anti-Doping Program. The List is updated annually following an extensive consultation process facilitated by WADA. The effective date of the List is 01 January 2025. The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. Below are some terms used in this List of Prohibited Substances and Prohibited Methods. Prohibited In-Competition Subject to a different period having been approved by WADA for a given sport, the In-Competition period shall in principle be the period commencing just before midnight (at 11:59 p.m.) on the day before a Competition in which the Athlete is scheduled to participate until the end of the Competition and the Sample collection process. Prohibited at all times This means that the substance or method is prohibited In- and Out-of-Competition as defined in the Code. Specified and non-Specified As per Article 4.2.2 of the World Anti-Doping Code, “for purposes of the application of Article 10, all Prohibited Substances shall be Specified Substances except as identified on the Prohibited List. No Prohibited Method shall be a Specified Method unless it is specifically identified as a Specified Method on the Prohibited List”. As per the comment to the article, “the Specified Substances and Methods identified in Article 4.2.2 should not in any way be considered less important or less dangerous than other doping substances or methods. Rather, they are simply substances and methods which are more likely to have been consumed or used by an Athlete for a purpose other than the enhancement of sport performance.” Substances of Abuse Pursuant to Article 4.2.3 of the Code, Substances of Abuse are substances that are identified as such because they are frequently abused in society outside of the context of sport. The following are designated Substances of Abuse: cocaine, diamorphine (heroin), methylenedioxymethamphetamine (MDMA/”ecstasy”), tetrahydrocannabinol (THC). THE 2025 PROHIBITED LIST WORLD ANTI-DOPING CODE VALID 1 JANUARY 2025 Published by: World Anti-Doping Agency Place Victoria, 800, rue du Square-Victoria, bureau 1700 Montréal (Québec) H3C 0B4 Canada URL: www.wada-ama.org Tel: +1 514 904 9232 Fax: +1 514 904 8650 E-mail: code@wada-ama.org 4 S0 Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times. This class covers many different substances including but not limited to BPC-157, 2,4- dinitrophenol (DNP), ryanodine receptor-1-calstabin complex stabilizers [e.g. S-107, S48168 (ARM210)] and troponin activators (e.g. reldesemtiv and tirasemtiv). PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) All prohibited substances in this class are Specified Substances. NON-APPROVED SUBSTANCES 5 • 1-Androstenediol (5ɑ-androst-1-ene-3ß, 17ß-diol) • 1-Androstenedione (5ɑ-androst-1-ene-3, 17-dione) • 1-Androsterone (3ɑ-hydroxy-5a-androst-1- ene-17-one) • 1-Epiandrosterone (3ß-hydroxy-5ɑ-androst- 1-ene-17-one) • 1-Testosterone (17ß-hydroxy-5ɑ-androst-1- en-3-one) • 4-Androstenediol (androst-4-ene-3ß, 17ß-diol) • 4-Hydroxytestosterone (4,17ß-dihydroxyandrost-4-en-3-one) • 5-Androstenedione (androst-5-ene-3,17-dione) • 7ɑ-Hydroxy-DHEA • 7ß-Hydroxy-DHEA • 7-Keto-DHEA • 11ß-Methyl-19-nortestosterone • 17ɑ-Methylepithiostanol (epistane) • 19-Norandrostenediol (estr-4-ene-3,17-diol) • 19-Norandrostenedione (estr-4-ene-3,17-dione) • Androst-4-ene-3,11,17- trione (11-ketoandrostenedione, adrenosterone) • Androstanolone (5ɑ-dihydrotestosterone, 17ß-hydroxy-5ɑ-androstan-3-one) • Androstenediol (androst-5-ene-3ß,17ß-diol) • Androstenedione (androst-4-ene-3,17-dione) • Bolasterone • Boldenone • Boldione (androsta-1,4-diene-3,17-dione) • Calusterone • Clostebol • Danazol ([1,2]oxazolo[4’,5’:2,3]pregna-4-en- 20-yn-17ɑ-ol) • Dehydrochlormethyltestosterone (4-chloro- 17ß-hydroxy-17ɑ-methylandrosta-1,4-dien-3- one) • Desoxymethyltestosterone (17ɑ-methyl- 5ɑ-androst-2-en-17ß-ol and 17ɑ-methyl-5ɑ- androst-3-en-17ß-ol) • Dimethandrolone (7ɑ,11ß-Dimethyl-19- nortestosterone) • Drostanolone • Epiandrosterone (3ß-hydroxy-5ɑ-androstan- 17-one) • Epi-dihydrotestosterone (17ß-hydroxy-5ß- androstan-3-one) • Epitestosterone • Ethylestrenol (19-norpregna-4-en-17ɑ-ol) • Fluoxymesterone • Formebolone • Furazabol (17ɑ-methyl [1,2,5] oxadiazolo[3’,4’:2,3]-5ɑ-androstan-17ß-ol) Anabolic agents are prohibited. When administered exogenously, including but not limited to: S1.1. ANABOLIC ANDROGENIC STEROIDS (AAS) S1 ANABOLIC AGENTS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) All prohibited substances in this class are non-Specified Substances. 6 S1 • Gestrinone • Mestanolone • Mesterolone • Metandienone (17ß-hydroxy-17ɑ- methylandrosta-1,4-dien-3-one) • Metenolone • Methandriol • Methasterone (17ß-hydroxy-2ɑ,17ɑ-dimethyl- 5ɑ-androstan-3-one) • Methyl-1-testosterone (17ß-hydroxy-17ɑ- methyl-5ɑ-androst-1-en-3-one) • Methylclostebol • Methyldienolone (17ß-hydroxy-17ɑ- methylestra-4,9-dien-3-one) • Methylnortestosterone (17ß-hydroxy-17ɑ- methylestr-4-en-3-one) • Methyltestosterone • Metribolone (methyltrienolone, 17ß-hydroxy- 17ɑ-methylestra-4,9,11-trien-3-one) • Mibolerone • Nandrolone (19-nortestosterone) • Norboletone • Norclostebol (4-chloro-17ß-ol-estr-4-en-3-one) • Norethandrolone • Oxabolone • Oxandrolone • Oxymesterone • Oxymetholone • Prasterone (dehydroepiandrosterone, DHEA, 3ß-hydroxyandrost-5-en-17-one) • Prostanozol (17ß-[(tetrahydropyran-2-yl)oxy]- 1’H-pyrazolo[3,4:2,3]-5ɑ-androstane) • Quinbolone • Stanozolol • Stenbolone • Testosterone • Tetrahydrogestrinone (17-hydroxy-18a- homo-19-nor-17ɑ-pregna-4,9,11-trien-3-one) • Tibolone • Trenbolone (17ß-hydroxyestr-4,9,11-trien-3- one) • Trestolone (7ɑ-Methyl-19-nortestosterone, MENT) and other substances with a similar chemical structure or similar biological effect(s). S1.1. ANABOLIC ANDROGENIC STEROIDS (AAS) (continued) S1.2. OTHER ANABOLIC AGENTS Including, but not limited to: Clenbuterol, osilodrostat, ractopamine, selective androgen receptor modulators [SARMs, e.g. andarine, enobosarm (ostarine), LGD-4033 (ligandrol), RAD140, S-23 and YK-11], zeranol and zilpaterol. ANABOLIC AGENTS (continued) 7 S2 Including, but not limited to: S2.1.1 Erythropoietin receptor agonists, e.g. darbepoetins (dEPO); erythropoietins (EPO); EPO-based constructs [e.g. EPO-Fc, methoxy polyethylene glycol-epoetin beta (CERA)]; EPO-mimetic agents and their constructs (e.g. CNTO-530, peginesatide). S2.1.2 Hypoxia-inducible factor (HIF) activating agents, e.g. cobalt; daprodustat (GSK1278863); IOX2; molidustat (BAY 85-3934); roxadustat (FG-4592); vadadustat (AKB-6548); xenon. S2.1.3 GATA inhibitors, e.g. K-11706. S2.1.4 Transforming growth factor beta (TGF-ß) signalling inhibitors, e.g. luspatercept; sotatercept. S2.1.5 Innate repair receptor agonists, e.g. asialo EPO; carbamylated EPO (CEPO). The following substances, and other substances with similar chemical structure or similar biological effect(s), are prohibited. S2.1. ERYTHROPOIETINS (EPO) AND AGENTS AFFECTING ERYTHROPOIESIS PEPTIDE HORMONES, GROWTH FACTORS, RELATED SUBSTANCES, AND MIMETICS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) All prohibited substances in this class are non-Specified Substances. 8 Including, but not limited to: • Fibroblast growth factors (FGFs) • Hepatocyte growth factor (HGF) • Insulin-like growth factor 1 (IGF-1, mecasermin) and its analogues • Mechano growth factors (MGFs) • Platelet-derived growth factor (PDGF) • Thymosin-ß4 and its derivatives e.g. TB-500 • Vascular endothelial growth factor (VEGF) and other growth factors or growth factor modulators affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching. S2.3. GROWTH FACTORS AND GROWTH FACTOR MODULATORS S2 PEPTIDE HORMONES, GROWTH FACTORS, RELATED SUBSTANCES, AND MIMETICS (continued) S2.2.1 Testosterone-stimulating peptides in males including, but not limited to: • chorionic gonadotrophin (CG), • luteinizing hormone (LH), • gonadotrophin- releasing hormone (GnRH, gonadorelin) and its agonist analogues (e.g. buserelin, deslorelin, goserelin, histrelin, leuprorelin, nafarelin and triptorelin), • kisspeptin and its agonist analogues S2.2.2 Corticotrophins and their releasing factors, e.g. corticorelin and tetracosactide S2.2.3 Growth hormone (GH), its analogues and fragments including, but not limited to: • growth hormone analogues, e.g. lonapegsomatropin, somapacitan and somatrogon • growth hormone fragments, e.g. AOD-9604 and hGH 176-191 S2.2.4 Growth hormone releasing factors, including, but not limited to: • growth hormone-releasing hormone (GHRH) and its analogues (e.g. CJC-1293, CJC-1295, sermorelin and tesamorelin) • growth hormone secretagogues (GHS) and their mimetics [e.g. anamorelin, capromorelin, ibutamoren (MK-677), ipamorelin, lenomorelin (ghrelin), macimorelin and tabimorelin] • GH-releasing peptides (GHRPs) [e.g. alexamorelin, examorelin (hexarelin), GHRP-1, GHRP-2 (pralmorelin), GHRP-3, GHRP-4, GHRP-5 and GHRP-6] S2.2. PEPTIDE HORMONES AND THEIR RELEASING FACTORS 9 S3 PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) All prohibited substances in this class are Specified Substances. All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited. Including, but not limited to: • Arformoterol • Fenoterol • Formoterol • Higenamine • Indacaterol • Levosalbutamol • Olodaterol • Procaterol • Reproterol • Salbutamol • Salmeterol • Terbutaline • Tretoquinol (trimetoquinol) • Tulobuterol • Vilanterol The presence in urine of salbutamol in excess of 1000 ng/mL or formoterol in excess of 40 ng/mL is not consistent with therapeutic use of the substance and will be considered as an Adverse Analytical Finding (AAF) unless the Athlete proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of a therapeutic dose (by inhalation) up to the maximum dose indicated above. NOTE • Inhaled salbutamol: maximum 1600 micrograms over 24 hours in divided doses not to exceed 600 micrograms over 8 hours starting from any dose; • Inhaled formoterol: maximum delivered dose of 54 micrograms over 24 hours in divided doses not to exceed 36 micrograms over 12 hours starting from any dose; • Inhaled salmeterol: maximum 200 micrograms over 24 hours; • Inhaled vilanterol: maximum 25 micrograms over 24 hours. EXCEPTIONS BETA-2 AGONISTS 10 S4 The following hormone and metabolic modulators are prohibited. Including, but not limited to: • 2-Androstenol (5ɑ-androst-2-en-17-ol) • 2-Androstenone (5ɑ-androst-2-en-17-one) • 3-Androstenol (5ɑ-androst-3-en-17-ol) • 3-Androstenone (5ɑ-androst-3-en-17-one) • 4-Androstene-3,6,17 trione (6-oxo) • Aminoglutethimide • Anastrozole • Androsta-1,4,6-triene-3,17-dione (androstatrienedione) • Androsta-3,5-diene-7,17-dione (arimistane) • Exemestane • Formestane • Letrozole • Testolactone S4.1. AROMATASE INHIBITORS Including, but not limited to: • Bazedoxifene • Clomifene • Cyclofenil • Elacestrant​ • Fulvestrant • Ospemifene • Raloxifene • Tamoxifen • Toremifene S4.2. ANTI-ESTROGENIC SUBSTANCES [ANTI-ESTROGENS AND SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS)] PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) Prohibited substances in classes S4.1 and S4.2 are Specified Substances. Those in classes S4.3 and S4.4 are non-Specified Substances. HORMONE AND METABOLIC MODULATORS 11 Including, but not limited to: • Activin A-neutralizing antibodies • Activin receptor IIB competitors such as: – Decoy activin receptors (e.g. ACE-031) • Anti-activin receptor IIB antibodies (e.g. bimagrumab) • Myostatin inhibitors such as: – Agents reducing or ablating myostatin expression – Myostatin-binding proteins (e.g. follistatin, myostatin propeptide) – Myostatin- or precursor-neutralizing antibodies (e.g. apitegromab, domagro- zumab, landogrozumab, stamulumab) S4.3. AGENTS PREVENTING ACTIVIN RECEPTOR IIB ACTIVATION S4.4.1 • Activators of the AMP-activated protein kinase (AMPK), e.g. AICAR, mitochondrial open reading frame of the 12S rRNA-c (MOTS-c); • Peroxisome proliferator-activated receptor delta (PPARδ) agonists, e.g. 2-(2-methyl- 4-((4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)methylthio)phenoxy) acetic acid (GW1516, GW501516) and; • Rev-erbɑ agonists, e.g. SR9009, SR9011 S4.4.2 Insulins and insulin-mimetics, e.g. S519, S597 S4.4.3 Meldonium S4.4.4 Trimetazidine S4.4. METABOLIC MODULATORS S4 HORMONE AND METABOLIC MODULATORS (continued) 12 S5 PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) All prohibited substances in this class are Specified Substances. All diuretics and masking agents, including all optical isomers, e.g. d- and l- where relevant, are prohibited. Including, but not limited to: • Diuretics such as: Acetazolamide; amiloride; bumetanide; canrenone; chlortalidone; etacrynic acid; furosemide; indapamide; metolazone; spironolactone; thiazides, e.g. bendroflumethiazide, chlorothiazide and hydrochlorothiazide; torasemide; triamterene; xipamide; • Vaptans, e.g. conivaptan, mozavaptan, tolvaptan; • Plasma expanders by intravenous administration such as: Albumin, dextran, hydroxyethyl starch, mannitol; • Desmopressin; • Probenecid; and other substances with a similar chemical structure or similar biological effect(s). DIURETICS AND MASKING AGENTS The detection in an Athlete’s Sample at all times or In-Competition, as applicable, of any quantity of the following substances subject to threshold limits: formoterol, salbutamol, cathine, ephedrine, methylephedrine and pseudoephedrine, in conjunction with a diuretic or masking agent (except topical ophthalmic administration of a carbonic anhydrase inhibitor or local administration of felypressin in dental anaesthesia), will be considered as an Adverse Analytical Finding (AAF) unless the Athlete has an approved Therapeutic Use Exemption (TUE) for that substance in addition to the one granted for the diuretic or masking agent. NOTE • Drospirenone; pamabrom; and topical ophthalmic administration of carbonic anhydrase inhibitors (e.g. dorzolamide, brinzolamide); • Local administration of felypressin in dental anaesthesia. EXCEPTIONS 13 PROHIBITED METHODS The following are prohibited: M1.1. The Administration or reintroduction of any quantity of autologous, allogenic (homologous) or heterologous blood, or red blood cell products of any origin into the circulatory system. M1.2. Artificially enhancing the uptake, transport or delivery of oxygen. Including, but not limited to: Perfluorochemicals; efaproxiral (RSR13); voxelotor and modified haemoglobin products, e.g. haemoglobin-based blood substitutes and microencapsulated haemoglobin products, excluding supplemental oxygen by inhalation. M1.3. Any form of intravascular manipulation of the blood or blood components by physical or chemical means. M1. MANIPULATION OF BLOOD AND BLOOD COMPONENTS The following are prohibited: M2.1. Tampering, or Attempting to Tamper, to alter the integrity and validity of Samples collected during Doping Control. Including, but not limited to: Sample substitution and/or adulteration, e.g. addition of proteases to Sample. M2.2. Intravenous infusions and/or injections of more than a total of 100 mL per 12-hour period except for those legitimately received in the course of hospital treatments, surgical procedures or clinical diagnostic investigations. M2. CHEMICAL AND PHYSICAL MANIPULATION The following, with the potential to enhance sport performance, are prohibited: M3.1. The use of nucleic acids or nucleic acid analogues that may alter genome sequences and/or gene expression by any mechanism. This includes but is not limited to gene editing, gene silencing and gene transfer technologies. M3.2. The use of normal or genetically modified cells. M3. GENE AND CELL DOPING PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) All prohibited methods in this class are non-Specified except methods in M2.2. which are Specified Methods. Donation of blood or blood components, including by apheresis, is not prohibited when performed in a collection center accredited by the relevant regulatory authority of the country in which it operates. NOTE 14 S6 All stimulants, including all optical isomers, e.g. d- and l- where relevant, are prohibited. A stimulant not expressly listed in this section is a Specified Substance. PROHIBITED IN-COMPETITION All prohibited substances in this class are Specified Substances except those in S6.A, which are non-Specified Substances. Substances of Abuse in this section: cocaine and methylenedioxymethamphetamine (MDMA / “ecstasy”) Stimulants include: • Adrafinil • Amfepramone • Amfetamine • Amfetaminil • Amiphenazole • Benfluorex • Benzylpiperazine • Bromantan • Clobenzorex • Cocaine • Cropropamide • Crotetamide • Fencamine • Fenetylline • Fenfluramine • Fenproporex • Fonturacetam [4-phenylpiracetam (carphedon)] • Furfenorex • Hydrafinil (fluorenol) • Lisdexamfetamine • Mefenorex • Mephentermine • Mesocarb • Metamfetamine(d-) • p-methylamfetamine • Modafinil • Norfenfluramine • Phendimetrazine • Phentermine • Prenylamine • Prolintane S6.A: NON-SPECIFIED STIMULANTS STIMULANTS 15 S6 Including, but not limited to: • 2-phenylpropan-1-amine (ß-methylphenylethyl- amine, BMPEA) • 3-Methylhexan-2-amine (1,2-dimethylpentylamine) • 4-Fluoromethylphenidate • 4-Methylhexan-2-amine (1,3-dimethylamylamine, 1,3 DMAA, methylhexanea- mine) • 4-Methylpentan-2-amine (1,3-dimethylbutylamine) • 5-Methylhexan-2-amine (1,4-dimethylamylamine, 1,4-dimethylpentylamine, 1,4-DMAA) • Benzfetamine • Cathine** • Cathinone and its ana- logues, e.g. mephedrone, methedrone, and ɑ - pyrrolidinovalerophenone • Dimetamfetamine (dimethylamphetamine) • Ephedrine*** • Epinephrine**** (adrenaline) • Etamivan • Ethylphenidate • Etilamfetamine • Etilefrine • Famprofazone • Fenbutrazate • Fencamfamin • Heptaminol • Hydroxyamfetamine (parahydroxyamphet- amine) • Isometheptene • Levmetamfetamine • Meclofenoxate • Methylenedioxymetham- phetamine • Methylephedrine*** • Methylnaphthidate [(±)-methyl-2-(naphthalen-2- yl)-2-(piperidin-2-yl)acetate] • Methylphenidate • Midodrine • Nikethamide • Norfenefrine • Octodrine (1,5-dimethyl- hexylamine) • Octopamine • Oxilofrine (methylsynephrine) • Pemoline • Pentetrazol • Phenethylamine and its derivatives • Phenmetrazine • Phenpromethamine • Propylhexedrine • Pseudoephedrine***** • Selegiline • Sibutramine • Solriamfetol • Strychnine • Tenamfetamine (methylenedioxyamphet- amine) • Tesofensine • Tuaminoheptane * Bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradrol, and synephrine: These substances are included in the 2025 Monitoring Program and are not considered Prohibited Substances. ** Cathine (d-norpseudoephedrine) and its l-isomer: Prohibited when its concentration in urine is greater than 5 micrograms per millilitre. *** Ephedrine and methylephedrine: Prohibited when the concentration of either in urine is greater than 10 micrograms per millilitre. **** Epinephrine (adrenaline): Not prohibited in local administration, e.g. nasal, ophthalmologic, or co-administration with local anaesthetic agents. ***** Pseudoephedrine: Prohibited when its concentration in urine is greater than 150 micrograms per millilitre. S6.B: SPECIFIED STIMULANTS • Clonidine, guanfacine; • Imidazoline derivatives for dermatological, nasal, ophthalmic or otic use (e.g. brimonidine, clonazoline, fenoxazoline, indanazoline, naphazoline, oxymetazoline, tetryzoline, tramazoline, xylometazoline) and those stimulants included in the 2025 Monitoring Program*. and other substances with a similar chemical structure or similar biological effect(s). STIMULANTS (continued) EXCEPTIONS 16 S7 • Buprenorphine • Dextromoramide • Diamorphine (heroin) • Fentanyl and its derivatives • Hydromorphone • Methadone • Morphine • Nicomorphine • Oxycodone • Oxymorphone • Pentazocine • Pethidine • Tramadol The following narcotics, including all optical isomers, e.g. d- and l- where relevant, are prohibited. PROHIBITED IN-COMPETITION All prohibited substances in this class are Specified Substances. Substance of Abuse in this section: diamorphine (heroin) NARCOTICS 17 S8 All natural and synthetic cannabinoids are prohibited, e.g. • In cannabis (hashish, marijuana) and cannabis products • Natural and synthetic tetrahydrocannabinols (THCs) • Synthetic cannabinoids that mimic the effects of THC PROHIBITED IN-COMPETITION All prohibited substances in this class are Specified Substances. Substance of Abuse in this section: tetrahydrocannabinol (THC) • Cannabidiol CANNABINOIDS EXCEPTIONS 18 S9 All glucocorticoids are prohibited when administered by any injectable, oral [including oromucosal (e.g. buccal, gingival, sublingual)] or rectal route. Including, but not limited to: • Beclometasone • Betamethasone • Budesonide • Ciclesonide • Cortisone • Deflazacort • Dexamethasone • Flunisolide • Fluocortolone • Fluticasone • Hydrocortisone • Methylprednisolone • Mometasone • Prednisolone • Prednisone • Triamcinolone acetonide PROHIBITED IN-COMPETITION All prohibited substances in this class are Specified Substances. GLUCOCORTICOIDS • Other routes of administration (including inhaled, and topical: dental-intracanal, dermal, intranasal, ophthalmological, otic and perianal) are not prohibited when used within the manufacturer’s licensed doses and therapeutic indications. NOTE 19 P1 Beta-blockers are prohibited In-Competition only, in the following sports, and also prohibited Out-of-Competition where indicated (*). • Archery (WA)* • Automobile (FIA) • Billiards (all disciplines) (WCBS) • Darts (WDF) • Golf (IGF) • Mini-Golf (WMF) • Shooting (ISSF, IPC)* • Underwater sports (CMAS)* in all subdisciplines of freediving, spearfishing and target shooting Including, but not limited to: • Acebutolol • Alprenolol • Atenolol • Betaxolol • Bisoprolol • Bunolol • Carteolol • Carvedilol • Celiprolol • Esmolol • Labetalol • Metipranolol • Metoprolol • Nadolol • Nebivolol • Oxprenolol • Pindolol • Propranolol • Sotalol • Timolol *Also prohibited Out-of-Competition PROHIBITED IN PARTICULAR SPORTS All prohibited substances in this class are Specified Substances. BETA-BLOCKERS 20 INDEX (±)-Methyl-2-(naphthalen-2-yl)-2- (piperidin-2-yl)acetate, 15 1-Androstenediol, 5 1-Androstenedione, 5 1-Androsterone, 5 1-Epiandrosterone, 5 1-Testosterone, 5 1,2-Dimethylpentylamine, 15 [1,2]Oxazolo[4’,5’:2,3]pregna-4-en-20- yn-17ɑ-ol), 5 1,3-Dimethylamylamine (1,3 DMAA), 15 1,3-Dimethylbutylamine, 15 1,4-Dimethylamylamine (1,4-DMAA), 15 1,4-Dimethylpentylamine, 15 1,5- Dimethyl-hexylamine, 15 2-Androstenol, 10 2-Androstenone, 10 2-Phenylpropan-1-amine, 15 2,4-Dinitrophenol (DNP), 4 3ɑ-Hydroxy-5ɑ-androst-1-ene-17-one, 5 3ß-Hydroxy-5ɑ-androst-1-ene-17-one, 5 3ß-Hydroxy-5ɑ-androstan-17-one, 5 3ß-Hydroxyandrost-5-en-17-one, 6 3-Androstenol, 10 3-Androstenone, 10 3-Methylhexan-2-amine, 15 4-Androstene-3,6,17 trione, 10 4-Androstenediol, 5 4-Chloro-17ß-hydroxy-17ɑ- methylandrosta-1,4-dien-3-one, 5 4-Chloro-17ß-ol-estr-4-en-3-one, 6 4-Fluoromethylphenidate, 15 4-Hydroxytestosterone, 5 4-Methylhexan-2-amine, 15 4-Methylpentan-2-amine, 15 4-Phenylpiracetam, 14 4,17ß-Dihydroxyandrost-4-en-3-one, 5 5ɑ-Androst-1-ene-3, 17-dione, 5 5ɑ-Androst-1-ene-3ß, 17ß-diol, 5 5ɑ-Androst-2-en-17-ol, 10 5ɑ-Androst-2-en-17-one, 10 5ɑ-Androst-3-en-17-ol, 10 5ɑ-Androst-3-en-17-one, 10 5ɑ-Dihydrotestosterone, 5 5-Androstenedione, 5 5-Methylhexan-2-amine, 15 6-Oxo, 10 7ɑ-Hydroxy-DHEA, 5 7ɑ,11ß-Dimethyl-19-nortestosterone, 5 7ɑ-Methyl-19-nortestosterone, 6 7ß-Hydroxy-DHEA, 5 7-Keto-DHEA, 5 11ß-Methyl-19-nortestosterone, 5 11-Ketoandrostenedione, 5 17ɑ-Methyl [1,2,5]oxadiazolo[3’,4’:2,3]- 5ɑ-androstan-17ß-ol, 5 17ɑ-Methyl-5ɑ-androst-2-en-17ß-ol, 5 17ɑ-Methyl-5ɑ-androst-3-en-17ß-ol, 5 17ɑ-Methylepithiostanol, 5 17ß-Hydroxy-2ɑ,17ɑ-dimethyl-5ɑ- androstan-3-one, 6 17ß-Hydroxy-5ɑ-androst-1-en-3-one, 5 17ß-Hydroxy-5ɑ-androstan-3-one, 5 17ß-Hydroxy-5ß-androstan-3-one, 5 17ß-hydroxy-17ɑ-methyl-5ɑ-androst-1- en-3-one, 6 17ß-Hydroxy-17ɑ-methylandrosta-1,4- dien-3-one, 6 17ß-Hydroxy-17ɑ-methylestr-4-en-3- one, 6 17ß-Hydroxy-17ɑ-methylestra-4,9-dien- 3-one, 6 17ß-Hydroxy-17ɑ-methylestra-4,9,11- trien-3-one, 6 17ß-Hydroxyestr-4,9,11-trien-3-one, 6 17ß-[(Tetrahydropyran-2-yl)oxy]-1’H- pyrazolo[3,4:2,3]-5ɑ-androstane, 6 17-Hydroxy-18a-homo-19-nor-17ɑ- pregna-4,9,11-trien-3-one, 6 19-Norandrostenediol, 5 19-Norandrostenedione, 5 19-Norpregna-4-en-17ɑ-ol, 5 19-Nortestosterone, 6 ɑ-Pyrrolidinovalerophenone, 15 ß-Methylphenylethylamine, 15 A ACE-031, 11 Acebutolol, 19 Acetazolamide, 12 Activators of the AMP-activated protein kinase (AMPK), 11 Activin A-neutralizing antibodies, 11 Activin receptor IIB competitors, 11 Adrafinil, 14 Adrenaline, 15 Adrenosterone, 5 AICAR, 11 Albumin, 12 Alexamorelin, 8 Alprenolol, 19 Amfepramone, 14 Amfetamine, 14 Amfetaminil, 14 Amiloride, 12 Aminoglutethimide, 10 Amiphenazole, 14 AMP-activated protein kinase (AMPK), 11 Anamorelin, 8 Anastrozole, 10 Andarine, 6 Androst-4-ene-3ß,17ß-diol, 5 Androst-4-ene-3,11,17- trione, 5 Androst-4-ene-3,17-dione, 5 Androst-5-ene-3ß,17ß-diol, 5 Androst-5-ene-3,17-dione, 5 Androsta-1,4,6-triene-3,17-dione, 10 Androsta-1,4-diene-3,17-dione, 5 Androsta-3,5-diene-7,17-dione, 10 Androstanolone, 5 Androstatrienedione, 10 Androstenediol, 5 Androstenedione, 5 Anti-activin receptor IIB antibodies, 11 AOD-9604, 8 Apheresis, 13 Apitegromab, 11 Arformoterol, 9 Arimistane, 10 ARM210, 4 Asialo EPO, 7 Atenolol, 19 B Bazedoxifene, 10 Beclometasone, 18 Bendroflumethiazide, 12 Benfluorex, 14 Benzfetamine, 15 Benzylpiperazine, 14 Betamethasone, 18 Betaxolol, 19 Bimagrumab, 11 Bisoprolol, 19 Blood, 13 Blood (autologous), 13 Blood (components), 13 Blood (heterologous), 13 Blood (homologous), 13 Blood manipulation, 13 BMPEA, 15 Bolasterone, 5 21 INDEX Boldenone, 5 Boldione, 5 BPC-157, 4 Brimonidine, 15 Brinzolamide, 12 Bromantan, 14 Budesonide, 18 Bumetanide, 12 Bunolol, 19 Buprenorphine, 16 Bupropion, 15 Buserelin, 8 C Caffeine, 15 Calusterone, 5 Cannabidiol, 17 Cannabis, 17 Canrenone, 12 Capromorelin, 8 Carbamylated EPO (CEPO), 7 Carphedon, 14 Carteolol, 19 Carvedilol, 19 Cathine, 12, 15 Cathinone, 15 Celiprolol, 19 Cell (doping), 13 Cell (genetically modified), 13 Cell (normal), 13 Cell (red blood), 13 Chlorothiazide, 12 Chlortalidone, 12 Chorionic Gonadotrophin (CG), 8 Ciclesonide, 18 CJC-1293, 8 CJC-1295, 8 Clenbuterol, 6 Clobenzorex, 14 Clomifene, 10 Clonazoline, 15 Clonidine, 15 Clostebol, 5 CNTO-530, 7 Cobalt, 7 Cocaine, 14 Conivaptan, 12 Corticorelin, 8 Corticotrophins, 8 Cortisone, 18 Cropropamide, 14 Crotetamide, 14 Cyclofenil, 10 D Danazol, 5 Daprodustat, 7 Darbepoetins (dEPO), 7 Deflazacort, 18 Dehydrochlormethyltestosterone, 5 Dehydroepiandrosterone (DHEA), 6 Deslorelin, 8 Desmopressin, 12 Desoxymethyltestosterone, 5 Dexamethasone, 18 Dextran, 12 Dextromoramide, 16 Diamorphine, 16 Dimetamfetamine, 15 Dimethandrolone, 5 Dimethylamphetamine, 15 Domagrozumab, 11 Dorzolamide, 12 Drospirenone, 12 Drostanolone, 5 E Ecstasy, 14 Efaproxiral (RSR13), 13 Elacestrant, 10 Enobosarm, 6 Ephedrine, 12, 15 Epiandrosterone, 5 Epi-dihydrotestosterone, 5 Epinephrine, 15 Epistane, 5 Epitestosterone, 5 EPO-based constructs, 7 EPO-Fc, 7 EPO-mimetic agents, 7 Erythropoietin receptor agonists, 7 Erythropoietins (EPO), 7 Esmolol, 19 Estr-4-ene-3,17-diol, 5 Estr-4-ene-3,17-dione, 5 Etacrynic acid, 12 Etamivan, 15 Ethylestrenol, 5 Ethylphenidate, 15 Etilamfetamine, 15 Etilefrine, 15 Examorelin, 8 Exemestane, 10 F Famprofazone, 15 Felypressin, 12 Fenbutrazate, 15 Fencamfamin, 15 Fencamine, 14 Fenetylline, 14 Fenfluramine, 14 Fenoterol, 9 Fenoxazoline, 15 Fenproporex, 14 Fentanyl, 16 Fibroblast growth factors (FGFs), 8 Flunisolide, 18 Fluocortolone, 18 Fluorenol, 14 Fluoxymesterone, 5 Fluticasone, 18 Follistatin, 11 Fonturacetam, 14 Formebolone, 5 Formestane, 10 Formoterol, 9, 12 Fulvestrant, 10 Furazabol, 5 Furfenorex, 14 Furosemide, 12 G GATA inhibitors, 7 Gene doping, 13 Gene editing, 13 Gene silencing, 13 Gene transfer, 13 Gestrinone, 6 Ghrelin, 8 GH-releasing peptides (GHRPs), 8 Gonadorelin, 8 Gonadotrophin-releasing hormone (GnRH), 8 Goserelin, 8 Growth hormone (GH), 8 Growth hormone secretagogues (GHS), 8 Guanfacine, 15 GW1516, 11 GW501516, 11 22 INDEX H Haemoglobin (products), 13 Haemoglobin (based blood substitutes), 13 Haemoglobin (microencapsulated products), 13 Hashish, 17 Hepatocyte growth factor (HGF), 8 Heptaminol, 15 Heroin, 16 Hexarelin, 8 hGH 176-191, 8 Higenamine, 9 Histrelin, 8 Hydrafinil, 14 Hydrochlorothiazide, 12 Hydrocortisone, 18 Hydromorphone, 16 Hydroxyamfetamine, 15 Hydroxyethyl starch, 12 Hypoxia-inducible factor (HIF) activating agents, 7 I Ibutamoren, 8 Imidazoline, 15 Indacaterol, 9 Indanazoline, 15 Indapamide, 12 Infusions, 13 Injections (> 100 mL), 13 Innate repair receptor agonists, 7 Insulin-like growth factor-1 (IGF-1), 8 Insulin-mimetics, 11 Insulins, 11 Intravenous infusions/injections, 13 IOX2, 7 Ipamorelin, 8 Isometheptene, 15 K K-11706, 7 Kisspeptin, 8 L Labetalol, 19 Landogrozumab, 11 Lenomorelin, 8 Letrozole, 10 Leuprorelin, 8 Levmetamfetamine, 15 Levosalbutamol, 9 LGD-4033, 6 Ligandrol, 6 Lisdexamfetamine, 14 Lonapegsomatropin, 8 Luspatercept, 7 Luteinizing hormone (LH), 8 M Macimorelin, 8 Mannitol, 12 Marijuana, 17 Mecasermin, 8 Mechano growth factors (MGFs), 8 Meclofenoxate, 15 Mefenorex, 14 Meldonium, 11 MENT, 6 Mephedrone, 15 Mephentermine, 14 Mesocarb, 14 Mestanolone, 6 Mesterolone, 6 Metamfetamine(d-), 14 Metandienone, 6 Metenolone, 6 Methadone, 16 Methandriol, 6 Methasterone, 6 Methedrone, 15 Methoxy polyethylene glycol-epoetin beta (CERA), 7 Methyl-1-testosterone, 6 Methylclostebol, 6 Methyldienolone, 6 Methylenedioxyamphetamine, 15 Methylenedioxymethamphetamine, 15 Methylephedrine, 12, 15 Methylhexaneamine, 15 Methylnaphtidate, 15 Methylnortestosterone, 6 Methylphenidate, 15 Methylprednisolone, 18 Methylsynephrine, 15 Methyltestosterone, 6 Methyltrienolone, 6 Metipranolol, 19 Metolazone, 12 Metoprolol, 19 Metribolone, 6 Mibolerone, 6 Midodrine, 15 Mitochondrial open reading frame of the 12S rRNA-c, 11 MK-677, 8 Modafinil, 14 Molidustat, 7 Mometasone, 18 Morphine, 16 MOTS-c, 11 Mozavaptan, 12 Myostatin inhibitors, 11 Myostatin precursor-neutralizing antibodies, 11 Myostatin propeptide, 11 Myostatin-binding proteins, 11 Myostatin-neutralizing antibodies, 11 N Nadolol, 19 Nafarelin, 8 Nandrolone, 6 Naphazoline, 15 Nebivolol, 19 Nicomorphine, 16 Nicotine, 15 Nikethamide, 15 Norboletone, 6 Norclostebol, 6 Norethandrolone, 6 Norfenefrine, 15 Norfenfluramine, 14 Nucleic acids, 13 Nucleic acid analogues, 13 O Octodrine, 15 Octopamine, 15 Olodaterol, 9 Osilodrostat, 6 Ospemifene, 10 Ostarine, 6 Oxabolone, 6 Oxandrolone, 6 Oxilofrine, 15 Oxprenolol, 19 Oxycodone, 16 Oxymesterone, 6 Oxymetazoline, 15 Oxymetholone, 6 Oxymorphone, 16 23 INDEX P Pamabrom, 12 Parahydroxyamphetamine, 15 Peginesatide, 7 Pemoline, 15 Pentazocine, 16 Pentetrazol, 15 Perfluorochemicals, 13 Peroxisome proliferator activated receptor delta agonists, 11 Pethidine, 16 Phendimetrazine, 14 Phenethylamine, 15 Phenmetrazine, 15 Phenpromethamine, 15 Phentermine, 14 Phenylephrine, 15 Phenylpropanolamine, 15 Pindolol, 19 Pipradrol, 15 Plasma expanders, 12 Platelet-derived growth factor (PDGF), 8 p-methylamfetamine, 14 Pralmorelin, 8 Prasterone, 6 Prednisolone, 18 Prednisone, 18 Prenylamine, 14 Probenecid, 12 Procaterol, 9 Prolintane, 14 Propranolol, 19 Propylhexedrine, 15 Prostanozol, 6 Proteases, 13 Pseudoephedrine, 12, 15 Q Quinbolone, 6 R RAD140, 6 Ractopamine, 6 Raloxifene, 10 Reldesemtiv, 4 Reproterol, 9 Rev-erbɑ agonists, 11 Roxadustat, 7 Ryanodine receptor-1-calstabin complex stabilizers, 4 S S-107, 4 S-23, 6 S48168, 4 S519, 11 S597, 11 Salbutamol, 9, 12 Salmeterol, 9 Selective androgen receptor modulators (SARMs), 6 Selegiline, 15 Sermorelin, 8 Sibutramine, 15 Solriamfetol, 15 Somapacitan, 8 Somatrogon, 8 Sotalol, 19 Sotatercept, 7 Spironolactone, 12 SR9009, 11 SR9011, 11 Stamulumab, 11 Stanozolol, 6 Stenbolone, 6 Strychnine, 15 Synephrine, 15 T Tabimorelin, 8 Tamoxifen, 10 Tampering, 13 TB-500, 8 Tenamfetamine, 15 Terbutaline, 9 Tesamorelin, 8 Tesofensine, 15 Testolactone, 10 Testosterone, 6 Testosterone-stimulating peptides 8 Tetracosactide, 8 Tetrahydrocannabinols, 17 Tetrahydrogestrinone, 6 Tetryzoline, 15 Thiazides, 12 Thymosin-ß4, 8 Tibolone, 6 Timolol, 19 Tirasemtiv, 4 Tolvaptan, 12 Torasemide, 12 Toremifene, 10 Tramadol, 16 Tramazoline, 15 Transforming growth factor beta (TGF-ß) signalling inhibitors, 7 Trenbolone, 6 Trestolone, 6 Tretoquinol, 9 Triamcinolone acetonide, 18 Triamterene, 12 Trimetazidine, 11 Trimetoquinol, 9 Triptorelin, 8 Troponin activators, 4 Tuaminoheptane, 15 Tulobuterol, 9 V Vadadustat (AKB-6548), 7 Vaptans, 12 Vascular endothelial growth factor (VEGF), 8 Vilanterol, 9 Voxelotor, 13 X Xenon, 7 Xipamide, 12 Xylometazoline, 15 Y YK-11, 6 Z Zeranol, 6 Zilpaterol, 6 www.wada-ama.org www.wada-ama.org https://www.wada-ama.org/en www.wada-ama.org www.wada-ama.org https://www.wada-ama.org/en

1 Summary of Major Modifications and Explanatory Notes 2026 Prohibited List SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) PROHIBITED SUBSTANCES S1. Anabolic agents • It was clarified in S1.1. that esters of the prohibited steroids are also prohibited. S3. Beta-2 Agonists • The dosing intervals of salmeterol were revised to avoid potential ergogenic effects beyond therapeutic action1. The maximum delivered dose is unchanged at 200 micrograms over 24 hours. S4. Hormone and Metabolic Modulators • 2-Phenylbenzo[h]chromen-4-one, also known as ɑ-naphthoflavone or 7,8-benzoflavone, was added as an example of an aromatase inhibitor. This synthetic substance has been found in supplements. • 5-N,6-N-bis(2-fluorophenyl)-[1,2,5]oxadiazolo[3,4-b]pyrazine-5,6-diamine, also known as BAM15, was added as an example of an activator of the AMP-activated protein kinase (AMPK). This synthetic substance has been found in supplements. S2. Peptide hormones, growth factors, related substances, and mimetics • Pegmolesatide was added as an example of a new EPO-mimetic agent. 1 Thoueille P, Danion A, Hostrup M, Petrou M, Deventer K, Buclin T, Girardin F, Mazzoni I, Rabin O, Guidi M. Pharmacometric-based eval- uation of salmeterol and its metabolite ɑ-hydroxysalmeterol in plasma and urine: practical implications for doping control. Submitted for publication. 2 PROHIBITED METHODS M1. Manipulation of Blood and Blood Components • It was clarified that withdrawal of blood or blood components is prohibited except for 1) analytical purposes including medical tests or Doping Control, or for 2) donation purposes performed in a collection center accredited by the relevant regulatory authority of the country in which it operates. Note that Platelet-Rich Plasma (PRP) and related procedures remain not prohibited. • The non-diagnostic use of carbon monoxide (CO) was added to the Prohibited Methods as a new section, M 1.4. It can increase erythropoiesis under certain conditions. The use of carbon monoxide for diagnostic purposes, such as total haemoglobin mass measurements or the determination of pulmonary diffusion capacity, is not prohibited. The current wording was chosen to differentiate between illicit use and the intake resulting from natural combustion processes (e.g. smoking), the environment (e. g. exhaust gases) or diagnostic procedures. M3. Gene and Cell Doping • Cell components (e.g. nuclei and organelles such as mitochondria and ribosomes) are added to the existing prohibition of using normal or genetically modified cells. 3 SUBSTANCES AND METHODS PROHIBITED IN-COMPETITION PROHIBITED SUBSTANCES S6. Stimulants • 2-[Bis(4-fluorophenyl)methylsulfinyl]acetamide (flmodafinil) and 2-[bis(4-fluorophenyl) methylsulfinyl]-N-hydroxyacetamide (fladrafinil) were added to the S6.A list of non- specified stimulants. These unapproved substances are potent analogs of modafinil and adrafinil, and are sold as supplements. S9. Glucocorticoids • The following clarification is added as a footnote to the Glucocorticoid Washout Table: “Use of sustained-release glucocorticoid formulations may result in detectable glucocorticoid levels past the washout period due to prolonged systemic absorption.” Route Glucocorticoid Washout period* Oral** All glucocorticoids; 3 days Except: triamcinolone; triamcinolone acetonide 10 days Intramuscular*** Betamethasone; dexameth- asone; methylprednisolone 5 days Prednisolone; prednisone 10 days Triamcinolone acetonide 60 days Local injections*** (including periarticular, in- tra-articular, peritendinous and intratendinous) All glucocorticoids; 3 days Except: prednisolone; prednisone; triamcinolone acetonide; triamcinolone hexacetonide 10 days Rectal All glucocorticoids; 3 days Except: triamcinolone dia- cetate; triamcinolone ace- tonide 10 days 4 • It is clarified that the urine monitoring of semaglutide includes also the monitoring of tirzepatide. * For further information on previous modifications and clarifications, please consult the Prohibited List Frequently Asked Questions at https://www.wada-ama.org/en/ prohibited-list#faq-anchor. MONITORING PROGRAM *The “washout period” refers to the time from the last administered dose to the time of the start of the In-Competition period (i.e. beginning at 11:59 p.m. on the day before a Competition in which the Athlete is scheduled to participate, unless a different period was approved by WADA for a given sport). This is to allow elimination of the glucocorticoid to below the reporting level. ** Oral routes also include e.g. oromucosal, buccal, gingival and sublingual. *** Use of sustained-release glucocorticoid formulations may result in detectable glucocorticoid levels past the washout period due to prolonged systemic absorption. • The Washout Period Table is also found in the List FAQ https://www.wada-ama.org/ en/prohibited-list#faq-anchor as well as in the Glucocorticoids and Therapeutic Use Exemptions Guidelines https://www.wada-ama.org/en/resources/therapeutic-use- exemption/glucocorticoids-and-therapeutic-use-exemptions-guidelines https://www.wada-ama.org/en/prohibited-list#faq-anchor https://www.wada-ama.org/en/prohibited-list#faq-anchor https://www.wada-ama.org/en/prohibited-list#faq-anchor https://www.wada-ama.org/en/prohibited-list#faq-anchor

The 2011 Prohibited List 18 September 2010 The World Anti-Doping Code THE 2011 PROHIBITED LIST INTERNATIONAL STANDARD The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. This List shall come into effect on 1 January 2011 The 2011 Prohibited List 18 September 2010 2 THE 2011 PROHIBITED LIST WORLD ANTI-DOPING CODE Valid 1 January 2011 All Prohibited Substances shall be considered as “Specified Substances” except Substances in classes S1, S2.1 to S2.5, S.4.4 and S6.a, and Prohibited Methods M1, M2 and M3. SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) S0. NON-APPROVED SUBSTANCES Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (i.e. drugs under pre-clinical or clinical development or discontinued) is prohibited at all times. PROHIBITED SUBSTANCES S1. ANABOLIC AGENTS Anabolic agents are prohibited. 1. Anabolic Androgenic Steroids (AAS) a. Exogenous* AAS, including: 1-androstenediol (5α-androst-1-ene-3β,17β-diol ); 1-androstenedione (5α- androst-1-ene-3,17-dione); bolandiol (19-norandrostenediol); bolasterone; boldenone; boldione (androsta-1,4-diene-3,17-dione); calusterone; clostebol; danazol (17α-ethynyl-17β-hydroxyandrost-4-eno[2,3-d]isoxazole); dehydrochlormethyltestosterone (4-chloro-17β-hydroxy-17α-methylandrosta- 1,4-dien-3-one); desoxymethyltestosterone (17α-methyl-5α-androst-2-en- 17β-ol); drostanolone; ethylestrenol (19-nor-17α-pregn-4-en-17-ol); fluoxymesterone; formebolone; furazabol (17β-hydroxy-17α-methyl-5α- The 2011 Prohibited List 18 September 2010 3 androstano[2,3-c]-furazan); gestrinone; 4-hydroxytestosterone (4,17β- dihydroxyandrost-4-en-3-one); mestanolone; mesterolone; metenolone; methandienone (17β-hydroxy-17α-methylandrosta-1,4-dien-3-one); methandriol; methasterone (2α, 17α-dimethyl-5α-androstane-3-one-17β-ol); methyldienolone (17β-hydroxy-17α-methylestra-4,9-dien-3-one); methyl-1- testosterone (17β-hydroxy-17α-methyl-5α-androst-1-en-3-one); methylnortestosterone (17β-hydroxy-17α-methylestr-4-en-3-one); methyltestosterone; metribolone (methyltrienolone, 17β-hydroxy-17α- methylestra-4,9,11-trien-3-one); mibolerone; nandrolone; 19- norandrostenedione (estr-4-ene-3,17-dione); norboletone; norclostebol; norethandrolone; oxabolone; oxandrolone; oxymesterone; oxymetholone; prostanozol (17β-hydroxy-5α-androstano[3,2-c] pyrazole); quinbolone; stanozolol; stenbolone; 1-testosterone (17β-hydroxy-5α-androst-1-en-3- one); tetrahydrogestrinone (18a-homo-pregna-4,9,11-trien-17β-ol-3-one); trenbolone; and other substances with a similar chemical structure or similar biological effect(s). b. Endogenous** AAS when administered exogenously: androstenediol (androst-5-ene-3β,17β-diol); androstenedione (androst-4-ene- 3,17-dione); dihydrotestosterone (17β-hydroxy-5α-androstan-3-one); prasterone (dehydroepiandrosterone, DHEA); testosterone and the following metabolites and isomers: 5α-androstane-3α,17α-diol; 5α-androstane-3α,17β-diol; 5α-androstane- 3β,17α-diol; 5α-androstane-3β,17β-diol; androst-4-ene-3α,17α-diol; androst-4-ene-3α,17β-diol; androst-4-ene-3β,17α-diol; androst-5-ene- 3α,17α-diol; androst-5-ene-3α,17β-diol; androst-5-ene-3β,17α-diol; 4-androstenediol (androst-4-ene-3β,17β-diol); 5-androstenedione (androst-5- ene-3,17-dione); epi-dihydrotestosterone; epitestosterone; 3α-hydroxy-5α- androstan-17-one; 3β-hydroxy-5α-androstan-17-one; 19- norandrosterone; 19-noretiocholanolone. 2. Other Anabolic Agents, including but not limited to: Clenbuterol, selective androgen receptor modulators (SARMs), tibolone, zeranol, zilpaterol. For purposes of this section: * “exogenous” refers to a substance which is not ordinarily capable of being produced by the body naturally. ** “endogenous” refers to a substance which is capable of being produced by the body naturally. The 2011 Prohibited List 18 September 2010 4 S2. PEPTIDE HORMONES, GROWTH FACTORS AND RELATED SUBSTANCES The following substances and their releasing factors are prohibited: 1. Erythropoiesis-Stimulating Agents [e.g. erythropoietin (EPO), darbepoetin (dEPO), hypoxia-inducible factor (HIF) stabilizers, methoxy polyethylene glycol-epoetin beta (CERA), peginesatide (Hematide)]; 2. Chorionic Gonadotrophin (CG) and Luteinizing Hormone (LH) in males; 3. Insulins; 4. Corticotrophins; 5. Growth Hormone (GH), Insulin-like Growth Factor-1 (IGF-1), Fibroblast Growth Factors (FGFs), Hepatocyte Growth Factor (HGF), Mechano Growth Factors (MGFs), Platelet-Derived Growth Factor (PDGF), Vascular-Endothelial Growth Factor (VEGF) as well as any other growth factor affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching; and other substances with similar chemical structure or similar biological effect(s). S3. BETA-2 AGONISTS All beta-2 agonists (including both optical isomers where relevant) are prohibited except salbutamol (maximum 1600 micrograms over 24 hours) and salmeterol when taken by inhalation in accordance with the manufacturers’ recommended therapeutic regime. The presence of salbutamol in urine in excess of 1000 ng/mL is presumed not to be an intended therapeutic use of the substance and will be considered as an Adverse Analytical Finding unless the Athlete proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of the use of a therapeutic dose (maximum 1600 micrograms over 24 hours) of inhaled salbutamol. The 2011 Prohibited List 18 September 2010 5 S4. HORMONE ANTAGONISTS AND MODULATORS The following classes are prohibited: 1. Aromatase inhibitors including, but not limited to: aminoglutethimide, anastrozole, androsta-1,4,6-triene-3,17-dione (androstatrienedione), 4-androstene-3,6,17 trione (6-oxo), exemestane, formestane, letrozole, testolactone. 2. Selective estrogen receptor modulators (SERMs) including, but not limited to: raloxifene, tamoxifen, toremifene. 3. Other anti-estrogenic substances including, but not limited to: clomiphene, cyclofenil, fulvestrant. 4. Agents modifying myostatin function(s) including, but not limited, to: myostatin inhibitors. S5. DIURETICS AND OTHER MASKING AGENTS Masking agents are prohibited. They include: Diuretics, desmopressin, plasma expanders (e.g. glycerol; intravenous administration of albumin, dextran, hydroxyethyl starch and mannitol), probenecid; and other substances with similar biological effect(s). Diuretics include: Acetazolamide, amiloride, bumetanide, canrenone, chlorthalidone, etacrynic acid, furosemide, indapamide, metolazone, spironolactone, thiazides (e.g. bendroflumethiazide, chlorothiazide, hydrochlorothiazide), triamterene; and other substances with a similar chemical structure or similar biological effect(s) (except drosperinone, pamabrom and topical dorzolamide and brinzolamide, which are not prohibited). The use In- and Out-of-Competition, as applicable, of any quantity of a substance subject to threshold limits (i.e. salbutamol, morphine, cathine, ephedrine, methylephedrine and pseudoephedrine) in conjunction with a diuretic or other masking agent requires the deliverance of a specific Therapeutic Use Exemption for that substance in addition to the one granted for the diuretic or other masking agent. The 2011 Prohibited List 18 September 2010 6 PROHIBITED METHODS M1. ENHANCEMENT OF OXYGEN TRANSFER The following are prohibited: 1. Blood doping, including the use of autologous, homologous or heterologous blood or red blood cell products of any origin. 2. Artificially enhancing the uptake, transport or delivery of oxygen, including, but not limited to, perfluorochemicals, efaproxiral (RSR13) and modified haemoglobin products (e.g. haemoglobin-based blood substitutes, microencapsulated haemoglobin products), excluding supplemental oxygen. M2. CHEMICAL AND PHYSICAL MANIPULATION The following is prohibited: 1. Tampering, or attempting to tamper, in order to alter the integrity and validity of Samples collected during Doping Control is prohibited. These include but are not limited to catheterisation, urine substitution and/or adulteration (e.g. proteases). 2. Intravenous infusions are prohibited except for those legitimately received in the course of hospital admissions or clinical investigations. 3. Sequential withdrawal, manipulation and reinfusion of whole blood into the circulatory system is prohibited. M3. GENE DOPING The following, with the potential to enhance sport performance, are prohibited: 1. The transfer of nucleic acids or nucleic acid sequences; 2. The use of normal or genetically modified cells; 3. The use of agents that directly or indirectly affect functions known to influence performance by altering gene expression. For example, Peroxisome Proliferator Activated Receptor δ (PPARδ) agonists (e.g. GW 1516) and PPARδ-AMP-activated protein kinase (AMPK) axis agonists (e.g. AICAR) are prohibited. The 2011 Prohibited List 18 September 2010 7 SUBSTANCES AND METHODS PROHIBITED IN-COMPETITION In addition to the categories S0 to S5 and M1 to M3 defined above, the following categories are prohibited In-Competition: PROHIBITED SUBSTANCES S6. STIMULANTS All stimulants (including both optical isomers where relevant) are prohibited, except imidazole derivatives for topical use and those stimulants included in the 2010 Monitoring Program*. Stimulants include: a: Non-Specified Stimulants: Adrafinil; amfepramone; amiphenazole; amphetamine; amphetaminil; benfluorex; benzphetamine; benzylpiperazine; bromantan; clobenzorex; cocaine; cropropamide; crotetamide; dimethylamphetamine; etilamphetamine; famprofazone; fencamine; fenetylline; fenfluramine; fenproporex; furfenorex; mefenorex; mephentermine; mesocarb; methamphetamine(d-); p-methylamphetamine; methylenedioxyamphetamine; methylenedioxymethamphetamine; modafinil; norfenfluramine; phendimetrazine; phenmetrazine; phentermine; 4-phenylpiracetam (carphedon); prenylamine; prolintane. A stimulant not expressly listed in this section is a Specified Substance. b: Specified Stimulants (examples): Adrenaline**; cathine***; ephedrine****; etamivan; etilefrine; fenbutrazate; fencamfamin; heptaminol; isometheptene; levmetamfetamine; meclofenoxate; methylephedrine****; methylhexaneamine (dimethylpentylamine); methylphenidate; nikethamide; norfenefrine; octopamine; oxilofrine; parahydroxyamphetamine; pemoline; pentetrazol; phenpromethamine; propylhexedrine; pseudoephedrine*****; selegiline; sibutramine; strychnine; tuaminoheptane; and other substances with a similar chemical structure or similar biological effect(s). The 2011 Prohibited List 18 September 2010 8 * The following substances included in the 2011 Monitoring Program (bupropion, caffeine, phenylephrine, phenylpropanolamine, pipradol, synephrine) are not considered as Prohibited Substances. ** Adrenaline associated with local anaesthetic agents or by local administration (e.g. nasal, ophthalmologic) is not prohibited. *** Cathine is prohibited when its concentration in urine is greater than 5 micrograms per milliliter. **** Each of ephedrine and methylephedrine is prohibited when its concentration in urine is greater than 10 micrograms per milliliter. ***** Pseudoephedrine is prohibited when its concentration in urine is greater than 150 micrograms per milliliter. S7. NARCOTICS The following are prohibited: Buprenorphine, dextromoramide, diamorphine (heroin), fentanyl and its derivatives, hydromorphone, methadone, morphine, oxycodone, oxymorphone, pentazocine, pethidine. S8. CANNABINOIDS Natural (e.g. cannabis, hashish, marijuana) or synthetic delta 9- tetrahydrocannabinol (THC) and cannabimimetics [e.g. “Spice” (containing JWH018, JWH073), HU-210] are prohibited. S9. GLUCOCORTICOSTEROIDS All glucocorticosteroids are prohibited when administered by oral, intravenous, intramuscular or rectal routes. The 2011 Prohibited List 18 September 2010 9 SUBSTANCES PROHIBITED IN PARTICULAR SPORTS P1. ALCOHOL Alcohol (ethanol) is prohibited In-Competition only, in the following sports. Detection will be conducted by analysis of breath and/or blood. The doping violation threshold (haematological values) is 0.10 g/L. • Aeronautic (FAI) • Archery (FITA) • Automobile (FIA) • Karate (WKF) • Motorcycling (FIM) • Ninepin and Tenpin Bowling (FIQ) • Powerboating (UIM) P2. BETA-BLOCKERS Unless otherwise specified, beta-blockers are prohibited In-Competition only, in the following sports. • Aeronautic (FAI) • Archery (FITA) (also prohibited Out-of-Competition) • Automobile (FIA) • Billiards and Snooker (WCBS) • Bobsleigh and Skeleton (FIBT) • Boules (CMSB) • Bridge (FMB) • Curling (WCF) • Darts (WDF) • Golf (IGF) • Motorcycling (FIM) • Modern Pentathlon (UIPM) for disciplines involving shooting • Ninepin and Tenpin Bowling (FIQ) • Powerboating (UIM) • Sailing (ISAF) for match race helms only • Shooting (ISSF, IPC) (also prohibited Out-of-Competition) • Skiing/Snowboarding (FIS) in ski jumping, freestyle aerials/halfpipe and snowboard halfpipe/big air • Wrestling (FILA) Beta-blockers include, but are not limited to, the following: Acebutolol, alprenolol, atenolol, betaxolol, bisoprolol, bunolol, carteolol, carvedilol, celiprolol, esmolol, labetalol, levobunolol, metipranolol, metoprolol, nadolol, oxprenolol, pindolol, propranolol, sotalol, timolol. THE 2011 PROHIBITED LIST SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) UAnabolic Androgenic Steroids (AAS) a. Exogenous* AAS, including: SUBSTANCES AND METHODS PROHIBITED IN-COMPETITION In addition to the categories S0 to S5 and M1 to M3 defined above, the following categories are prohibited In-Competition: US6. STIMULANTS US8. CANNABINOIDS US9. GLUCOCORTICOSTEROIDS All glucocorticosteroids are prohibited when administered by oral, intravenous, intramuscular or rectal routes. UP1. ALCOHOL Aeronautic (FAI) Archery (FITA) Automobile (FIA) Karate (WKF) Motorcycling (FIM) UP2. BETA-BLOCKERS

The 2011 Prohibited List 18 September 2010 The World Anti-Doping Code THE 2011 PROHIBITED LIST INTERNATIONAL STANDARD The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. This List shall come into effect on 1 January 2011 The 2011 Prohibited List 18 September 2010 2 THE 2011 PROHIBITED LIST WORLD ANTI-DOPING CODE Valid 1 January 2011 All Prohibited Substances shall be considered as “Specified Substances” except Substances in classes S1, S2.1 to S2.5, S.4.4 and S6.a, and Prohibited Methods M1, M2 and M3. SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) S0. NON-APPROVED SUBSTANCES Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (i.e. drugs under pre-clinical or clinical development or discontinued) is prohibited at all times. PROHIBITED SUBSTANCES S1. ANABOLIC AGENTS Anabolic agents are prohibited. 1. Anabolic Androgenic Steroids (AAS) a. Exogenous* AAS, including: 1-androstenediol (5α-androst-1-ene-3β,17β-diol ); 1-androstenedione (5α- androst-1-ene-3,17-dione); bolandiol (19-norandrostenediol); bolasterone; boldenone; boldione (androsta-1,4-diene-3,17-dione); calusterone; clostebol; danazol (17α-ethynyl-17β-hydroxyandrost-4-eno[2,3-d]isoxazole); dehydrochlormethyltestosterone (4-chloro-17β-hydroxy-17α-methylandrosta- 1,4-dien-3-one); desoxymethyltestosterone (17α-methyl-5α-androst-2-en- 17β-ol); drostanolone; ethylestrenol (19-nor-17α-pregn-4-en-17-ol); fluoxymesterone; formebolone; furazabol (17β-hydroxy-17α-methyl-5α- The 2011 Prohibited List 18 September 2010 3 androstano[2,3-c]-furazan); gestrinone; 4-hydroxytestosterone (4,17β- dihydroxyandrost-4-en-3-one); mestanolone; mesterolone; metenolone; methandienone (17β-hydroxy-17α-methylandrosta-1,4-dien-3-one); methandriol; methasterone (2α, 17α-dimethyl-5α-androstane-3-one-17β-ol); methyldienolone (17β-hydroxy-17α-methylestra-4,9-dien-3-one); methyl-1- testosterone (17β-hydroxy-17α-methyl-5α-androst-1-en-3-one); methylnortestosterone (17β-hydroxy-17α-methylestr-4-en-3-one); methyltestosterone; metribolone (methyltrienolone, 17β-hydroxy-17α- methylestra-4,9,11-trien-3-one); mibolerone; nandrolone; 19- norandrostenedione (estr-4-ene-3,17-dione); norboletone; norclostebol; norethandrolone; oxabolone; oxandrolone; oxymesterone; oxymetholone; prostanozol (17β-hydroxy-5α-androstano[3,2-c] pyrazole); quinbolone; stanozolol; stenbolone; 1-testosterone (17β-hydroxy-5α-androst-1-en-3- one); tetrahydrogestrinone (18a-homo-pregna-4,9,11-trien-17β-ol-3-one); trenbolone; and other substances with a similar chemical structure or similar biological effect(s). b. Endogenous** AAS when administered exogenously: androstenediol (androst-5-ene-3β,17β-diol); androstenedione (androst-4-ene- 3,17-dione); dihydrotestosterone (17β-hydroxy-5α-androstan-3-one); prasterone (dehydroepiandrosterone, DHEA); testosterone and the following metabolites and isomers: 5α-androstane-3α,17α-diol; 5α-androstane-3α,17β-diol; 5α-androstane- 3β,17α-diol; 5α-androstane-3β,17β-diol; androst-4-ene-3α,17α-diol; androst-4-ene-3α,17β-diol; androst-4-ene-3β,17α-diol; androst-5-ene- 3α,17α-diol; androst-5-ene-3α,17β-diol; androst-5-ene-3β,17α-diol; 4-androstenediol (androst-4-ene-3β,17β-diol); 5-androstenedione (androst-5- ene-3,17-dione); epi-dihydrotestosterone; epitestosterone; 3α-hydroxy-5α- androstan-17-one; 3β-hydroxy-5α-androstan-17-one; 19- norandrosterone; 19-noretiocholanolone. 2. Other Anabolic Agents, including but not limited to: Clenbuterol, selective androgen receptor modulators (SARMs), tibolone, zeranol, zilpaterol. For purposes of this section: * “exogenous” refers to a substance which is not ordinarily capable of being produced by the body naturally. ** “endogenous” refers to a substance which is capable of being produced by the body naturally. The 2011 Prohibited List 18 September 2010 4 S2. PEPTIDE HORMONES, GROWTH FACTORS AND RELATED SUBSTANCES The following substances and their releasing factors are prohibited: 1. Erythropoiesis-Stimulating Agents [e.g. erythropoietin (EPO), darbepoetin (dEPO), hypoxia-inducible factor (HIF) stabilizers, methoxy polyethylene glycol-epoetin beta (CERA), peginesatide (Hematide)]; 2. Chorionic Gonadotrophin (CG) and Luteinizing Hormone (LH) in males; 3. Insulins; 4. Corticotrophins; 5. Growth Hormone (GH), Insulin-like Growth Factor-1 (IGF-1), Fibroblast Growth Factors (FGFs), Hepatocyte Growth Factor (HGF), Mechano Growth Factors (MGFs), Platelet-Derived Growth Factor (PDGF), Vascular-Endothelial Growth Factor (VEGF) as well as any other growth factor affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching; and other substances with similar chemical structure or similar biological effect(s). S3. BETA-2 AGONISTS All beta-2 agonists (including both optical isomers where relevant) are prohibited except salbutamol (maximum 1600 micrograms over 24 hours) and salmeterol when taken by inhalation in accordance with the manufacturers’ recommended therapeutic regime. The presence of salbutamol in urine in excess of 1000 ng/mL is presumed not to be an intended therapeutic use of the substance and will be considered as an Adverse Analytical Finding unless the Athlete proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of the use of a therapeutic dose (maximum 1600 micrograms over 24 hours) of inhaled salbutamol. The 2011 Prohibited List 18 September 2010 5 S4. HORMONE ANTAGONISTS AND MODULATORS The following classes are prohibited: 1. Aromatase inhibitors including, but not limited to: aminoglutethimide, anastrozole, androsta-1,4,6-triene-3,17-dione (androstatrienedione), 4-androstene-3,6,17 trione (6-oxo), exemestane, formestane, letrozole, testolactone. 2. Selective estrogen receptor modulators (SERMs) including, but not limited to: raloxifene, tamoxifen, toremifene. 3. Other anti-estrogenic substances including, but not limited to: clomiphene, cyclofenil, fulvestrant. 4. Agents modifying myostatin function(s) including, but not limited, to: myostatin inhibitors. S5. DIURETICS AND OTHER MASKING AGENTS Masking agents are prohibited. They include: Diuretics, desmopressin, plasma expanders (e.g. glycerol; intravenous administration of albumin, dextran, hydroxyethyl starch and mannitol), probenecid; and other substances with similar biological effect(s). Diuretics include: Acetazolamide, amiloride, bumetanide, canrenone, chlorthalidone, etacrynic acid, furosemide, indapamide, metolazone, spironolactone, thiazides (e.g. bendroflumethiazide, chlorothiazide, hydrochlorothiazide), triamterene; and other substances with a similar chemical structure or similar biological effect(s) (except drosperinone, pamabrom and topical dorzolamide and brinzolamide, which are not prohibited). The use In- and Out-of-Competition, as applicable, of any quantity of a substance subject to threshold limits (i.e. salbutamol, morphine, cathine, ephedrine, methylephedrine and pseudoephedrine) in conjunction with a diuretic or other masking agent requires the deliverance of a specific Therapeutic Use Exemption for that substance in addition to the one granted for the diuretic or other masking agent. The 2011 Prohibited List 18 September 2010 6 PROHIBITED METHODS M1. ENHANCEMENT OF OXYGEN TRANSFER The following are prohibited: 1. Blood doping, including the use of autologous, homologous or heterologous blood or red blood cell products of any origin. 2. Artificially enhancing the uptake, transport or delivery of oxygen, including, but not limited to, perfluorochemicals, efaproxiral (RSR13) and modified haemoglobin products (e.g. haemoglobin-based blood substitutes, microencapsulated haemoglobin products), excluding supplemental oxygen. M2. CHEMICAL AND PHYSICAL MANIPULATION The following is prohibited: 1. Tampering, or attempting to tamper, in order to alter the integrity and validity of Samples collected during Doping Control is prohibited. These include but are not limited to catheterisation, urine substitution and/or adulteration (e.g. proteases). 2. Intravenous infusions are prohibited except for those legitimately received in the course of hospital admissions or clinical investigations. 3. Sequential withdrawal, manipulation and reinfusion of whole blood into the circulatory system is prohibited. M3. GENE DOPING The following, with the potential to enhance sport performance, are prohibited: 1. The transfer of nucleic acids or nucleic acid sequences; 2. The use of normal or genetically modified cells; 3. The use of agents that directly or indirectly affect functions known to influence performance by altering gene expression. For example, Peroxisome Proliferator Activated Receptor δ (PPARδ) agonists (e.g. GW 1516) and PPARδ-AMP-activated protein kinase (AMPK) axis agonists (e.g. AICAR) are prohibited. The 2011 Prohibited List 18 September 2010 7 SUBSTANCES AND METHODS PROHIBITED IN-COMPETITION In addition to the categories S0 to S5 and M1 to M3 defined above, the following categories are prohibited In-Competition: PROHIBITED SUBSTANCES S6. STIMULANTS All stimulants (including both optical isomers where relevant) are prohibited, except imidazole derivatives for topical use and those stimulants included in the 2010 Monitoring Program*. Stimulants include: a: Non-Specified Stimulants: Adrafinil; amfepramone; amiphenazole; amphetamine; amphetaminil; benfluorex; benzphetamine; benzylpiperazine; bromantan; clobenzorex; cocaine; cropropamide; crotetamide; dimethylamphetamine; etilamphetamine; famprofazone; fencamine; fenetylline; fenfluramine; fenproporex; furfenorex; mefenorex; mephentermine; mesocarb; methamphetamine(d-); p-methylamphetamine; methylenedioxyamphetamine; methylenedioxymethamphetamine; modafinil; norfenfluramine; phendimetrazine; phenmetrazine; phentermine; 4-phenylpiracetam (carphedon); prenylamine; prolintane. A stimulant not expressly listed in this section is a Specified Substance. b: Specified Stimulants (examples): Adrenaline**; cathine***; ephedrine****; etamivan; etilefrine; fenbutrazate; fencamfamin; heptaminol; isometheptene; levmetamfetamine; meclofenoxate; methylephedrine****; methylhexaneamine (dimethylpentylamine); methylphenidate; nikethamide; norfenefrine; octopamine; oxilofrine; parahydroxyamphetamine; pemoline; pentetrazol; phenpromethamine; propylhexedrine; pseudoephedrine*****; selegiline; sibutramine; strychnine; tuaminoheptane; and other substances with a similar chemical structure or similar biological effect(s). The 2011 Prohibited List 18 September 2010 8 * The following substances included in the 2011 Monitoring Program (bupropion, caffeine, phenylephrine, phenylpropanolamine, pipradol, synephrine) are not considered as Prohibited Substances. ** Adrenaline associated with local anaesthetic agents or by local administration (e.g. nasal, ophthalmologic) is not prohibited. *** Cathine is prohibited when its concentration in urine is greater than 5 micrograms per milliliter. **** Each of ephedrine and methylephedrine is prohibited when its concentration in urine is greater than 10 micrograms per milliliter. ***** Pseudoephedrine is prohibited when its concentration in urine is greater than 150 micrograms per milliliter. S7. NARCOTICS The following are prohibited: Buprenorphine, dextromoramide, diamorphine (heroin), fentanyl and its derivatives, hydromorphone, methadone, morphine, oxycodone, oxymorphone, pentazocine, pethidine. S8. CANNABINOIDS Natural (e.g. cannabis, hashish, marijuana) or synthetic delta 9- tetrahydrocannabinol (THC) and cannabimimetics [e.g. “Spice” (containing JWH018, JWH073), HU-210] are prohibited. S9. GLUCOCORTICOSTEROIDS All glucocorticosteroids are prohibited when administered by oral, intravenous, intramuscular or rectal routes. The 2011 Prohibited List 18 September 2010 9 SUBSTANCES PROHIBITED IN PARTICULAR SPORTS P1. ALCOHOL Alcohol (ethanol) is prohibited In-Competition only, in the following sports. Detection will be conducted by analysis of breath and/or blood. The doping violation threshold (haematological values) is 0.10 g/L. • Aeronautic (FAI) • Archery (FITA) • Automobile (FIA) • Karate (WKF) • Motorcycling (FIM) • Ninepin and Tenpin Bowling (FIQ) • Powerboating (UIM) P2. BETA-BLOCKERS Unless otherwise specified, beta-blockers are prohibited In-Competition only, in the following sports. • Aeronautic (FAI) • Archery (FITA) (also prohibited Out-of-Competition) • Automobile (FIA) • Billiards and Snooker (WCBS) • Bobsleigh and Skeleton (FIBT) • Boules (CMSB) • Bridge (FMB) • Curling (WCF) • Darts (WDF) • Golf (IGF) • Motorcycling (FIM) • Modern Pentathlon (UIPM) for disciplines involving shooting • Ninepin and Tenpin Bowling (FIQ) • Powerboating (UIM) • Sailing (ISAF) for match race helms only • Shooting (ISSF, IPC) (also prohibited Out-of-Competition) • Skiing/Snowboarding (FIS) in ski jumping, freestyle aerials/halfpipe and snowboard halfpipe/big air • Wrestling (FILA) Beta-blockers include, but are not limited to, the following: Acebutolol, alprenolol, atenolol, betaxolol, bisoprolol, bunolol, carteolol, carvedilol, celiprolol, esmolol, labetalol, levobunolol, metipranolol, metoprolol, nadolol, oxprenolol, pindolol, propranolol, sotalol, timolol. THE 2011 PROHIBITED LIST SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) UAnabolic Androgenic Steroids (AAS) a. Exogenous* AAS, including: SUBSTANCES AND METHODS PROHIBITED IN-COMPETITION In addition to the categories S0 to S5 and M1 to M3 defined above, the following categories are prohibited In-Competition: US6. STIMULANTS US8. CANNABINOIDS US9. GLUCOCORTICOSTEROIDS All glucocorticosteroids are prohibited when administered by oral, intravenous, intramuscular or rectal routes. UP1. ALCOHOL Aeronautic (FAI) Archery (FITA) Automobile (FIA) Karate (WKF) Motorcycling (FIM) UP2. BETA-BLOCKERS

1 Summary of Major Modifications and Explanatory Notes 2023 Prohibited List SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) PROHIBITED SUBSTANCES S1. Anabolic Agents • Androst-4-ene-3,11,17-trione (11-ketoandrostenedione, adrenosterone) is now listed as an example. In the body, it is converted to 11-ketotestosterone and both are androgens already prohibited as metabolites of androstenedione and testosterone, respectively. • The substance 17ɑ-methylepithiostanol (commonly referred to as epistane) is the 17-methylated analog to thiodrol (Shionogi, Japan) and converts in vivo to the prohibited anabolic agent desoxymethyltestosterone. Hence, per definition, 17ɑ-methylepithiostanol is also prohibited under S1. In order to unequivocally document the prohibited status of 17ɑ-methylepithiostanol, the substance was added as an additional example. • Ractopamine, a beta-adrenergic agonist approved in some countries as a growth promoter for animals, was added to the list of examples under S1.2. • S-23 and YK-11 were listed as examples of SARMs in S1.2. S4. Hormone and Metabolic Modulators • S4.3 was updated to include antibodies of precursors of myostatin and as example, apitegromab was added. • The numbering was reformatted for clarity but there was no change in classification. 2 S5. Diuretics and Masking Agents • The introductory language of the section was revised to harmonize with other sections of the List. • Torasemide is added as an example of a diuretic and is already named in a WADA Technical Document (TD MRPL) and a WADA Technical Letter (TL24). • It was clarified that a Therapeutic Use Exemption is not required for topical ophthalmic administration of a carbonic anhydrase inhibitor (e.g. dorzolamide, brinzolamine) or for local administration of felypressin in dental anesthesia in conjunction with a threshold substance. 3 PROHIBITED METHODS M1. Manipulation of Blood and Blood Components • Voxelotor was added as an example, as it alters the ability of hemoglobin to release oxygen in the body, thereby enhancing arterial oxygen saturation. As a side effect, it increases serum erythropoietin, which has been shown to result in higher hemoglobin concentration in healthy individuals. 4 S6. Stimulants • 1,3-dimethylamylamine and 1,3 DMAA were added as alternative common names for 4-methylhexan-2-amine, while 1,4-dimethylamylamine and 1,4-DMAA were included as synonyms of 5-methylhexan-2-amine. • Solriamfetol was included in S6b due to its activity as a dopamine and norepinephrine reuptake inhibitor resulting in increases in brain levels of these neurotransmitters and consequent stimulant behavioral effects in preclinical species and in humans. • Tetryzoline was added as an imidazoline derivative under Exceptions. In addition, it is clarified that otic administration of imidazoline derivatives is not prohibited. S7. Narcotics SUBSTANCES AND METHODS PROHIBITED IN-COMPETITION PROHIBITED SUBSTANCES 1 a) Holgado D, Zandonai T, Zabala M, Hopker J, Perakakis P, Luque-Casado A, Ciria L, Guerra-Hernandez E, Sanabria D. Tramadol effects on physical performance and sustained attention during a 20-min indoor cycling time-trial: A randomised controlled trial. J Sci Med Sport. 2018 Jul;21(7):654-660. b) Mauger L, Thomas T, Smith S, Fennell C. (2022). Is tramadol a performance enhancing drug? A randomised controlled trial. British Association of Sport and Exercise Medicine Conference, 26-27 May 2022, Brighton, UK. https://basem.co.uk/wp-content/uploads/2022/08/Mauger_BASEM-Abstract.pdf https://www.wada-ama.org/en/resources/funded-scientific-research/tramadol-performance-enhancing-drug • Tramadol has been on the WADA Monitoring Program for some years. Monitoring data has indicated significant Use in sports including cycling, rugby and football. Tramadol abuse, with its dose-dependent risks of physical dependence, opiate addiction and overdoses in the general population, is of concern and has led to it being a controlled drug in many countries. Research studies funded by WADA1 have confirmed the potential for tramadol to enhance physical performance in sports. Consequently, as proposed in the draft 2023 Prohibited List circulated for consultation to stakeholders in May 2022, WADA’s Executive Committee approved, at its 23 September 2022 meeting, prohibiting tramadol during the In-Competition period. However, in order to thoroughly and widely communicate the rule changes and to allow sufficient time for information and education, the Executive Committee decided to introduce the prohibition of tramadol and the implementation of the new rule on 1 January 2024. A one-year delay in implementation will allow Athletes and medical personnel to better prepare for the change, Laboratories to update their procedures, and sports authorities to develop educational tools. S9. Glucocorticoids • It was clarified that otic administration of glucocorticoids is not prohibited. 5 P1. Beta-Blockers • At the request of the World Mini-Golf Federation (WMF), it was agreed to include mini- golf as a sport where beta-blockers are prohibited. The skills required for mini-golf are similar to others found in sports disciplines where beta-blockers are prohibited. • At the request of the World Under Water Federation (CMAS) beta-blockers will be prohibited Out-of-competition as well as In-competition in all subdisciplines of freediving, spearfishing and target shooting. SUBSTANCES PROHIBITED IN PARTICULAR SPORTS 6 • Dermorphin and its analogs were added to detect patterns of use in sport In- competition. • GnRH analogs in females under 18 years were added to detect patterns of use in sport In- and Out-of-competition. • Hypoxen (polyhydroxyphenylene thiosulfonate sodium) was added to evaluate misuse in sport In- and Out-of-competition. * For further information on previous modifications and clarifications, please consult the Prohibited List Frequently Asked Questions at https://www.wada-ama.org/en/ prohibited-list#faq-anchor. MONITORING PROGRAM https://www.wada-ama.org/en/prohibited-list#faq-anchor https://www.wada-ama.org/en/prohibited-list#faq-anchor 7 ADDENDUM Background • Following receipt of requests from a small number of stakeholders to remove (three national anti-doping organizations and one sports federation) or review (two anti-doping organizations) the prohibited In-competition status of cannabis from the Prohibited List, the WADA Executive Committee endorsed, during its meeting of September 2021, a recommendation of the WADA List Expert Advisory Group (LiEAG) to initiate a scientific review of the status of cannabis in 2022. • At present, the main psychoactive component of cannabis, delta9-tetrahydrocannabinol (THC), is prohibited In-competition and is reported as an Adverse Analytical Finding (AAF) by WADA-accredited laboratories when the urinary concentration- of carboxy- THC exceeds a threshold of 150 ng/mL with a Decision Limit of 180 ng/mL. This threshold was significantly increased in 2013 from 15 ng/mL in order to minimize the number of AAFs In-competition due to potential Use of THC Out-of-competition. This means that with the current threshold, Athletes most at risk of testing positive are those who have consumed significant quantities of THC close to In-competition Doping Control or are chronic users. • The 2021 World Anti-Doping Code (Code) incorporated the new Article 4.2.3 on Substances of Abuse for purposes of sanctioning under Code Article 10. Substances of Abuse are specifically identified on the Prohibited List because they are frequently abused in society outside of the context of sport. In this regard, the LiEAG identified THC as a Substance of Abuse for the 2021 Prohibited List, meaning that if the Athlete can establish that the THC use occurred Out-of-Competition and was unrelated to sport performance, the standard period of Ineligibility is three months, which may be reduced to one month if the Athlete satisfactorily completes an approved Substance of Abuse treatment program. While it is too early to evaluate the full impact of this new rule on sanctions for THC, preliminary data from 2021 indicates an increase in one- and three- month sanctions, suggesting that this provision is being applied. • Under the World Anti-Doping Program, the approach to cannabis on the Prohibited List has therefore evolved chronologically as follows: 2013: The urinary threshold increased from 15 ng/mL to 150 ng/mL with a Decision Limit of 180 ng/ ml. This significantly affected the number of AAFs, from an average of between 400-500 per annum in the years 2009-2012 to fewer than 100 in 2021. 2018: Cannabidiol (CBD) was removed from the Prohibited List, allowing Athletes who wish to use it to have access to the non-psychoactive component of cannabis. 2021: The inclusion of the Substance of Abuse provision in the Code significantly reduced the length of Ineligibility sanctions from a potential two (or even four) years previously to three (or even one) month(s) today for Athletes that can establish that the THC use occurred Out-of-Competition and was unrelated to sport performance. Under Article 9 of the Code, the Athlete will still lose their medal, prize and result. S8. Cannabinoids 8 The Review Process: • Since September 2021, the LiEAG, which is composed of external, international experts in pharmacology, forensic toxicology, drugs of abuse, analytical science, pharmacy, sports medicine, chemistry, endocrinology, internal medicine, regulatory affairs, peptides and growth factors and hematology embarked on a full de novo review of the status of delta9-tetrahydrocannabinol (THC) in sport. This extensive review focused on the three criteria set forth by Article 4.3 of the 2021 Code, namely: a. Medical or other scientific evidence, pharmacological effect or experience that the substance or method, alone or in combination with other substances or methods, has the potential to enhance or enhances sport performance; b. Medical or other scientific evidence, pharmacological effects or experience that the Use of the substance or method represents an actual or potential health risk to the Athlete; c. WADA’s determination that the Use of the substance or method contravenes the spirit of sport described in the introduction to the Code. • Under Code Article 4.3, a substance or method must meet at least two of these three criteria to be considered for inclusion in the Prohibited List. • Two subgroups of members of the LiEAG were formed, one to evaluate the effects of THC on performance enhancement (LiEAG-PE) and the other to assess the health risks (LiEAG-H). All existing scientific and medical publications related to these two topics were reviewed, as well as testimonials from Athletes who were/are cannabis users, available publicly, including in published surveys. • This scientific literature review was subsequently discussed with four world-renowned independent, external international experts (Ad-Hoc THC Expert Group) specialized in the pharmacology, toxicology, psychiatry and behavioral properties of THC and cannabinoids, to ensure that all relevant publications had been included and that all relevant scientific and medical aspects had been appropriately evaluated. The experts confirmed that the information review had been extensive and that all relevant data and aspects of the impact of THC on health and performance enhancement had been properly examined. • With respect to the Spirit of Sport criterion, the LiEAG Chair consulted with the WADA Ethics Expert Advisory Group (Ethics EAG). The Ethics EAG considered cannabis Use, at this time, to be against the Spirit of Sport across a cluster of areas listed in the Code, in particular: • Health • Excellence in Performance • Character and Education • Respect for rules and laws • Respect for self and other participants They also noted that: • Further research should be undertaken or supported in relation to Athletes’ perceptions of cannabis Use but also in relation to its potential (including placebo-induced) enhancing effects. These are areas of uncertainty owing to a lack of robust evidence. 9 Conclusions: After a thorough assessment and discussion under WADA Code Article 4.3, the LiEAG concluded that: a. There is compelling medical evidence that Use of THC is a risk for health, mainly neurological, that has a significant impact on the health of young individuals, a cohort which is overrepresented in Athletes. b. The current body of objective evidence does not support THC enhancement of physiological performance, while the potential for performance enhancement through neuropsychological effects still cannot be excluded. c. In consideration of the values encompassed by the Spirit of Sport as outlined by the Ethics EAG, and noting in particular that respect for self and other participants includes the safety of fellow-competitors, the Use of THC In-competition violates the Spirit of Sport. Based on these three criteria defined by the Code, on the scientific evidence available, THC meets the criteria to be included on the List. • Levels to trigger an Anti-Doping Rule Violation In-competition are such that they would be problematic on medical grounds for a competing Athlete, or indicative of a chronic habitual user. The present rule is not, as sometimes perceived or represented, an excessive incursion into private lifestyles. Nevertheless, and mindful of shifting public attitudes and laws in certain countries, the weight of evidence and argument, along with broad international restrictive regulatory laws and policies, supports the continuance of cannabis on the Prohibited List at this time. • The LiEAG Chair also consulted with the members of the WADA Athlete Committee to seek their opinions on the Use of cannabis in sport. The meeting reflected the range of opinions and views of the Athlete community. • In total, there were 10 consultative meetings held prior to the latest meeting of the LiEAG on 25-26 April 2022: • three by the LiEAG-PE • two by the LiEAG-H • one between the LiEAG Chair and the Athlete Committee Chair • one between the LiEAG Chair and the Athlete Committee • one between the LiEAG Chair and the Ethics EAG • one between the Ad-Hoc THC Expert Group and the LiEAG-PE • one between the Ad-Hoc THC Expert Group and the LiEAG-H 10 Future considerations: • These conclusions are based on the currently available scientific literature. From the extensive review conducted, it was evident that there is a lack of robust studies evaluating the performance enhancing effects of THC at both the physical and mental level. While anecdotal, self-reported evidence is available, further clinical studies are required to rigorously determine the neuropsychological impact of THC on performance. However, it is also acknowledged that such studies may be difficult to design. For example, it would require enrolling volunteers actively consuming THC, which in most countries is illegal; it would not be a truly blinded placebo study because the subject would feel the effect of THC leading to possible positive bias (to show it has performance enhancing effects and thus should be prohibited) or negative bias (to support exclusion from the List); it would be difficult to re-create the stress of a competition; and it is very unlikely that high level Athletes could be included as volunteers. Therefore, only those using cannabis and in regions where THC use is legal could be recruited, and in an Out-of-competition setting, with a risk of positive or negative bias. • As with all substances that are prohibited In-competition only, Athletes in regions where cannabis use is legal are advised to refrain from consuming cannabis for a number of days before the start of competition.

1 Summary of Major Modifications and Explanatory Notes 2023 Prohibited List SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) PROHIBITED SUBSTANCES S1. Anabolic Agents • Androst-4-ene-3,11,17-trione (11-ketoandrostenedione, adrenosterone) is now listed as an example. In the body, it is converted to 11-ketotestosterone and both are androgens already prohibited as metabolites of androstenedione and testosterone, respectively. • The substance 17ɑ-methylepithiostanol (commonly referred to as epistane) is the 17-methylated analog to thiodrol (Shionogi, Japan) and converts in vivo to the prohibited anabolic agent desoxymethyltestosterone. Hence, per definition, 17ɑ-methylepithiostanol is also prohibited under S1. In order to unequivocally document the prohibited status of 17ɑ-methylepithiostanol, the substance was added as an additional example. • Ractopamine, a beta-adrenergic agonist approved in some countries as a growth promoter for animals, was added to the list of examples under S1.2. • S-23 and YK-11 were listed as examples of SARMs in S1.2. S4. Hormone and Metabolic Modulators • S4.3 was updated to include antibodies of precursors of myostatin and as example, apitegromab was added. • The numbering was reformatted for clarity but there was no change in classification. 2 S5. Diuretics and Masking Agents • The introductory language of the section was revised to harmonize with other sections of the List. • Torasemide is added as an example of a diuretic and is already named in a WADA Technical Document (TD MRPL) and a WADA Technical Letter (TL24). • It was clarified that a Therapeutic Use Exemption is not required for topical ophthalmic administration of a carbonic anhydrase inhibitor (e.g. dorzolamide, brinzolamine) or for local administration of felypressin in dental anesthesia in conjunction with a threshold substance. 3 PROHIBITED METHODS M1. Manipulation of Blood and Blood Components • Voxelotor was added as an example, as it alters the ability of hemoglobin to release oxygen in the body, thereby enhancing arterial oxygen saturation. As a side effect, it increases serum erythropoietin, which has been shown to result in higher hemoglobin concentration in healthy individuals. 4 S6. Stimulants • 1,3-dimethylamylamine and 1,3 DMAA were added as alternative common names for 4-methylhexan-2-amine, while 1,4-dimethylamylamine and 1,4-DMAA were included as synonyms of 5-methylhexan-2-amine. • Solriamfetol was included in S6b due to its activity as a dopamine and norepinephrine reuptake inhibitor resulting in increases in brain levels of these neurotransmitters and consequent stimulant behavioral effects in preclinical species and in humans. • Tetryzoline was added as an imidazoline derivative under Exceptions. In addition, it is clarified that otic administration of imidazoline derivatives is not prohibited. S7. Narcotics SUBSTANCES AND METHODS PROHIBITED IN-COMPETITION PROHIBITED SUBSTANCES 1 a) Holgado D, Zandonai T, Zabala M, Hopker J, Perakakis P, Luque-Casado A, Ciria L, Guerra-Hernandez E, Sanabria D. Tramadol effects on physical performance and sustained attention during a 20-min indoor cycling time-trial: A randomised controlled trial. J Sci Med Sport. 2018 Jul;21(7):654-660. b) Mauger L, Thomas T, Smith S, Fennell C. (2022). Is tramadol a performance enhancing drug? A randomised controlled trial. British Association of Sport and Exercise Medicine Conference, 26-27 May 2022, Brighton, UK. https://basem.co.uk/wp-content/uploads/2022/08/Mauger_BASEM-Abstract.pdf https://www.wada-ama.org/en/resources/funded-scientific-research/tramadol-performance-enhancing-drug • Tramadol has been on the WADA Monitoring Program for some years. Monitoring data has indicated significant Use in sports including cycling, rugby and football. Tramadol abuse, with its dose-dependent risks of physical dependence, opiate addiction and overdoses in the general population, is of concern and has led to it being a controlled drug in many countries. Research studies funded by WADA1 have confirmed the potential for tramadol to enhance physical performance in sports. Consequently, as proposed in the draft 2023 Prohibited List circulated for consultation to stakeholders in May 2022, WADA’s Executive Committee approved, at its 23 September 2022 meeting, prohibiting tramadol during the In-Competition period. However, in order to thoroughly and widely communicate the rule changes and to allow sufficient time for information and education, the Executive Committee decided to introduce the prohibition of tramadol and the implementation of the new rule on 1 January 2024. A one-year delay in implementation will allow Athletes and medical personnel to better prepare for the change, Laboratories to update their procedures, and sports authorities to develop educational tools. S9. Glucocorticoids • It was clarified that otic administration of glucocorticoids is not prohibited. 5 P1. Beta-Blockers • At the request of the World Mini-Golf Federation (WMF), it was agreed to include mini- golf as a sport where beta-blockers are prohibited. The skills required for mini-golf are similar to others found in sports disciplines where beta-blockers are prohibited. • At the request of the World Under Water Federation (CMAS) beta-blockers will be prohibited Out-of-competition as well as In-competition in all subdisciplines of freediving, spearfishing and target shooting. SUBSTANCES PROHIBITED IN PARTICULAR SPORTS 6 • Dermorphin and its analogs were added to detect patterns of use in sport In- competition. • GnRH analogs in females under 18 years were added to detect patterns of use in sport In- and Out-of-competition. • Hypoxen (polyhydroxyphenylene thiosulfonate sodium) was added to evaluate misuse in sport In- and Out-of-competition. * For further information on previous modifications and clarifications, please consult the Prohibited List Frequently Asked Questions at https://www.wada-ama.org/en/ prohibited-list#faq-anchor. MONITORING PROGRAM https://www.wada-ama.org/en/prohibited-list#faq-anchor https://www.wada-ama.org/en/prohibited-list#faq-anchor 7 ADDENDUM Background • Following receipt of requests from a small number of stakeholders to remove (three national anti-doping organizations and one sports federation) or review (two anti-doping organizations) the prohibited In-competition status of cannabis from the Prohibited List, the WADA Executive Committee endorsed, during its meeting of September 2021, a recommendation of the WADA List Expert Advisory Group (LiEAG) to initiate a scientific review of the status of cannabis in 2022. • At present, the main psychoactive component of cannabis, delta9-tetrahydrocannabinol (THC), is prohibited In-competition and is reported as an Adverse Analytical Finding (AAF) by WADA-accredited laboratories when the urinary concentration- of carboxy- THC exceeds a threshold of 150 ng/mL with a Decision Limit of 180 ng/mL. This threshold was significantly increased in 2013 from 15 ng/mL in order to minimize the number of AAFs In-competition due to potential Use of THC Out-of-competition. This means that with the current threshold, Athletes most at risk of testing positive are those who have consumed significant quantities of THC close to In-competition Doping Control or are chronic users. • The 2021 World Anti-Doping Code (Code) incorporated the new Article 4.2.3 on Substances of Abuse for purposes of sanctioning under Code Article 10. Substances of Abuse are specifically identified on the Prohibited List because they are frequently abused in society outside of the context of sport. In this regard, the LiEAG identified THC as a Substance of Abuse for the 2021 Prohibited List, meaning that if the Athlete can establish that the THC use occurred Out-of-Competition and was unrelated to sport performance, the standard period of Ineligibility is three months, which may be reduced to one month if the Athlete satisfactorily completes an approved Substance of Abuse treatment program. While it is too early to evaluate the full impact of this new rule on sanctions for THC, preliminary data from 2021 indicates an increase in one- and three- month sanctions, suggesting that this provision is being applied. • Under the World Anti-Doping Program, the approach to cannabis on the Prohibited List has therefore evolved chronologically as follows: 2013: The urinary threshold increased from 15 ng/mL to 150 ng/mL with a Decision Limit of 180 ng/ ml. This significantly affected the number of AAFs, from an average of between 400-500 per annum in the years 2009-2012 to fewer than 100 in 2021. 2018: Cannabidiol (CBD) was removed from the Prohibited List, allowing Athletes who wish to use it to have access to the non-psychoactive component of cannabis. 2021: The inclusion of the Substance of Abuse provision in the Code significantly reduced the length of Ineligibility sanctions from a potential two (or even four) years previously to three (or even one) month(s) today for Athletes that can establish that the THC use occurred Out-of-Competition and was unrelated to sport performance. Under Article 9 of the Code, the Athlete will still lose their medal, prize and result. S8. Cannabinoids 8 The Review Process: • Since September 2021, the LiEAG, which is composed of external, international experts in pharmacology, forensic toxicology, drugs of abuse, analytical science, pharmacy, sports medicine, chemistry, endocrinology, internal medicine, regulatory affairs, peptides and growth factors and hematology embarked on a full de novo review of the status of delta9-tetrahydrocannabinol (THC) in sport. This extensive review focused on the three criteria set forth by Article 4.3 of the 2021 Code, namely: a. Medical or other scientific evidence, pharmacological effect or experience that the substance or method, alone or in combination with other substances or methods, has the potential to enhance or enhances sport performance; b. Medical or other scientific evidence, pharmacological effects or experience that the Use of the substance or method represents an actual or potential health risk to the Athlete; c. WADA’s determination that the Use of the substance or method contravenes the spirit of sport described in the introduction to the Code. • Under Code Article 4.3, a substance or method must meet at least two of these three criteria to be considered for inclusion in the Prohibited List. • Two subgroups of members of the LiEAG were formed, one to evaluate the effects of THC on performance enhancement (LiEAG-PE) and the other to assess the health risks (LiEAG-H). All existing scientific and medical publications related to these two topics were reviewed, as well as testimonials from Athletes who were/are cannabis users, available publicly, including in published surveys. • This scientific literature review was subsequently discussed with four world-renowned independent, external international experts (Ad-Hoc THC Expert Group) specialized in the pharmacology, toxicology, psychiatry and behavioral properties of THC and cannabinoids, to ensure that all relevant publications had been included and that all relevant scientific and medical aspects had been appropriately evaluated. The experts confirmed that the information review had been extensive and that all relevant data and aspects of the impact of THC on health and performance enhancement had been properly examined. • With respect to the Spirit of Sport criterion, the LiEAG Chair consulted with the WADA Ethics Expert Advisory Group (Ethics EAG). The Ethics EAG considered cannabis Use, at this time, to be against the Spirit of Sport across a cluster of areas listed in the Code, in particular: • Health • Excellence in Performance • Character and Education • Respect for rules and laws • Respect for self and other participants They also noted that: • Further research should be undertaken or supported in relation to Athletes’ perceptions of cannabis Use but also in relation to its potential (including placebo-induced) enhancing effects. These are areas of uncertainty owing to a lack of robust evidence. 9 Conclusions: After a thorough assessment and discussion under WADA Code Article 4.3, the LiEAG concluded that: a. There is compelling medical evidence that Use of THC is a risk for health, mainly neurological, that has a significant impact on the health of young individuals, a cohort which is overrepresented in Athletes. b. The current body of objective evidence does not support THC enhancement of physiological performance, while the potential for performance enhancement through neuropsychological effects still cannot be excluded. c. In consideration of the values encompassed by the Spirit of Sport as outlined by the Ethics EAG, and noting in particular that respect for self and other participants includes the safety of fellow-competitors, the Use of THC In-competition violates the Spirit of Sport. Based on these three criteria defined by the Code, on the scientific evidence available, THC meets the criteria to be included on the List. • Levels to trigger an Anti-Doping Rule Violation In-competition are such that they would be problematic on medical grounds for a competing Athlete, or indicative of a chronic habitual user. The present rule is not, as sometimes perceived or represented, an excessive incursion into private lifestyles. Nevertheless, and mindful of shifting public attitudes and laws in certain countries, the weight of evidence and argument, along with broad international restrictive regulatory laws and policies, supports the continuance of cannabis on the Prohibited List at this time. • The LiEAG Chair also consulted with the members of the WADA Athlete Committee to seek their opinions on the Use of cannabis in sport. The meeting reflected the range of opinions and views of the Athlete community. • In total, there were 10 consultative meetings held prior to the latest meeting of the LiEAG on 25-26 April 2022: • three by the LiEAG-PE • two by the LiEAG-H • one between the LiEAG Chair and the Athlete Committee Chair • one between the LiEAG Chair and the Athlete Committee • one between the LiEAG Chair and the Ethics EAG • one between the Ad-Hoc THC Expert Group and the LiEAG-PE • one between the Ad-Hoc THC Expert Group and the LiEAG-H 10 Future considerations: • These conclusions are based on the currently available scientific literature. From the extensive review conducted, it was evident that there is a lack of robust studies evaluating the performance enhancing effects of THC at both the physical and mental level. While anecdotal, self-reported evidence is available, further clinical studies are required to rigorously determine the neuropsychological impact of THC on performance. However, it is also acknowledged that such studies may be difficult to design. For example, it would require enrolling volunteers actively consuming THC, which in most countries is illegal; it would not be a truly blinded placebo study because the subject would feel the effect of THC leading to possible positive bias (to show it has performance enhancing effects and thus should be prohibited) or negative bias (to support exclusion from the List); it would be difficult to re-create the stress of a competition; and it is very unlikely that high level Athletes could be included as volunteers. Therefore, only those using cannabis and in regions where THC use is legal could be recruited, and in an Out-of-competition setting, with a risk of positive or negative bias. • As with all substances that are prohibited In-competition only, Athletes in regions where cannabis use is legal are advised to refrain from consuming cannabis for a number of days before the start of competition.

1 September 19, 2009 2010 Prohibited List Summary of Major Modifications INTRODUCTORY PARAGRAPH The introductory sentence on the use of drugs limited to medically justified indications has been deleted. The reference to Specified Substances has been amended in accordance with changes introduced in section S2. SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF- COMPETITION) S1: Anabolic Agents The International Nonproprietary Name (INN) for methyltrienolone has been included (metribolone) Comment S1.1b, including revisions, is addressed in another WADA document (Technical Document MRPL). S2. Peptide Hormones, Growth Factors and Related Substances In order to better define the substances within this category, the title has been revised to “Peptide Hormones, Growth Factors and Related Substances”. To reflect the growing number of new erythropoeisis-stimulating substances available, methoxy polyethylene glycol-epoetin beta (CERA) has been added as an example. The issue of growth factors enhancing certain functions was addressed in more detail. Additional examples of growth factors affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching [e.g. Platelet-derived Growth Factor (PDGF), Fibroblast Growth Factors (FGFs), Vascular-Endothelial Growth Factor (VEGF), Hepatocyte Growth Factor (HGF)] were included. The status of Platelet-derived preparations (e.g. Platelet Rich Plasma, “blood spinning”) has been clarified. Comment S2 is addressed in another WADA document (Technical Document MRPL). 2 S3. Beta-2 Agonists The use of salbutamol and salmeterol by inhalation no longer requires a TUE but a declaration of Use. It is specified that the maximum dose for the controlled pharmacokinetic study cannot exceed the maximum therapeutic dose for inhaled salbutamol (1600 µg/day). S4. Hormone antagonists and Modulators Two examples of aromatase inhibitors, androstene-3,6,17 trione (6-oxo) and androsta-1,4,6-triene-3,17-dione (androstatrienedione) have been added in view of their wide availability as components of nutritional supplements. S5. Diuretics and Other masking Agents The status of glycerol (oral and intravenous) as a plasma expander was clarified and is now included as another example. The non-prohibited status of pamabrom was clarified because it is a weak diuretic largely available as a combined over-the-counter medication for pre- menstrual/menstrual symptoms. PROHIBITED METHODS M1. Enhancement of Oxygen Transfer Supplemental oxygen is no longer prohibited. M2. Chemical and Physical Manipulation Proteases have been added as an example of sample adulteration. The status of intravenous infusions has been reviewed and now reads: “Intravenous infusions are prohibited except for those legitimately received in the course of hospital admissions or clinical investigations.” M3. Gene Doping For clarification purposes the gene doping definition was reworded and split into 2 points. 3 SUBSTANCES AND METHODS PROHIBITED IN-COMPETITION S6. Stimulants Three stimulants, namely benfluorex, prenylamine, both known to metabolize to non-specified stimulants (amphetamine or norfenfluramine) as well as methylhexeneamine, a non-therapeutic substance, were added to the closed list of non-specified stimulants. Until 2003, the stimulant pseudoephedrine had been prohibited in sports with a threshold of 25 μg/mL. Pseudoephedrine has been included in the Monitoring Program since 2004. Results from the Monitoring Program over the past 5 years have shown a sustained increase in urinary concentrations of pseudoephedrine. In addition, there is clear evidence of abuse in some sports and some regions which show clusters of samples with high pseudoephedrine concentrations many times in excess of concentrations normally found. Furthermore, the available literature demonstrates scientific proof of its performance enhancing effects at certain doses. Therefore, the List Committee has reintroduced pseudoephedrine as a specified stimulant in the 2010 Prohibited List at a urinary threshold of 150 µg/mL based on the results from controlled excretion studies as well as the literature. Given the wide availability of pseudoephedrine-containing medicines, WADA recommends that the reintroduction of pseudoephedrine is supported by active information/education campaign by all stakeholders. Although pseudoephedrine is now prohibited, it will remain in the Monitoring Program for urinary concentrations below 150 µg/mL. S8. Cannabinoids It is clarified that synthetic cannabinoids are covered by this section. SUBSTANCES PROHIBITED IN PARTICULAR SPORTS P1. Alcohol and P2. Beta-blockers As the responsibility for testing in the sports of Boules and Archery has been transferred from the International Paralympic Committee (IPC) to the World Bowling Federation and the International Archery Federation (FITA), respectively, references to the IPC have been deleted.